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The MCV Quarterly ceases publication with this issue. No
journal of this type can be self-supporting and we bow to the inevitable reality of inflation.
The idea of the Quarterly came from Sarni Sa"id. Almost single
handed he cajoled and coerced the Dean of the School of Medicine
into .finding the money for publication. Throughout its existence
MCV/Q has remained true to its stated purpose of disseminating
"scientific information from all sources'~ resisting several attempts
to convert it into a "house journal" or popular newssheet. In essence,
it has been the printed pivot of continuing education in the medical
school.
It is hard to name the people behind the success, albeit temporary, of MCV/Q. The editors, of course-Sarni Said and Fair
Goodale-but even more so the Managing Editors-the last of whom
was Mary Park Johnson; the cover designer--Raymond Gearywhose eye catching, balanced designs have been a feature of the
Quarterly since its inception; and.finally, the Deans of the School of
Medicine-Drs. Kinloch Nelson, Warren Pierse, andjesse Steinfeld.
"Publish or perish" is an aca,demic aphorism today. Regretfully, we perish-but at least we published for sixteen enjoyable
years.
FJS

THE MEDICAL COLLEGE OF VIRGINIA
SCHOOL OF MEDICINE
Continuing Education Programs for 1982
DERMATOLOGY AND INTERNAL MEDICINE
Date: February 12-14, 1982
Location: The Homestead, Hot Springs, Virginia
Tuition and Fees: $220.000
A first time presentation providing the dermatologist and the internist with current concepts in diagnosis
and management of skin disorders with systemic manifestations and systemic diseases involving the
skin . The format includes lecture, discussion , and workshops .

PEDIATRIC RADIOLOGY
Date: February 28-March 4, 1982
Location: The Williamsburg Lodge, Williamsburg , Virginia
Tuition and Fees: $330.00
Radiologists and other treating pediqtric diseases are presented with the newer techniques available in
diagnosis. Some of the topics include Ultrasound, UT!, Pneumonia, Generalized Orthopedic Diseases
and Lesions of the Lungs.

RETINAL DISEASES AND OCULAR TUMORS
Date: March 19-21, 1982
Location: The Williamsburg Lodge, Williamsburg, Virginia
·
Tuition and Fees: $250.00
An in-depth exploration of the clinical diagnosis and management of retinal disease and ocular tumors.
Practicing ophthalmologists are invited to hear lectures, participate in small group sessions, and bring
difficult cases for consultation with MCV and guest faculty.

CLINICAL CONCERNS IN PRIMARY CARE
Date: April 16-18, 1982
Location: The Hospitality House, Williamsburg, Virginia
Tuition and Fees: $225.00
Primary care physicians are involved in workshops planned around three major areas of concern:
hematology, infectious qisease, and oncology. Topics include: anemias, work-up and management of
the bleeding patient, upper respiratory infections, abuse of antibiotics, treatable cancers and early
diagnosis, and management of common cancers.

SPRINGFEST: A CME PROGRAM IN PEDIATRICS
Date: April 22-24, 1982
Location: The Hospitality House, Williamsburg, Virginia
Tuition and Fees: To be announced
Behavioral aspects, dermatology, office emergencies, and other selected topics are explored for new
clinical information, implications, issues, and answers. Pediatricians share in le9tures, discussions, and
small group sessions .

EMERGENCY MEDICINE
Date: April 23-25, 1982
Location: Quality Inn-Fort Magruder, Williamsburg, Virginia
Tuition and Fees: $195.00
Lectures and workshops designed to provide emergency room and office based physicians with
practical clinical approaches to basic medical and surgical emergencies. Some of the topics are
sprains/strains, common anorectal problems, cardiac drugs, arrhythmias, splinting , and suture techniques.
·

HANS BERGER DAY: EEG SYMPOSIUM
Date: May 17- 18, 1982
Location: Baruch Auditorium , Richmond, Virginia
Tu ition and Fees: To be announced
Designed for physicians and other health professionals who use EEG as a diagnostic tool. Topics
include intractable seizures , cerebral death , stroke , and degenerative diseases of the brain.

RECENT TRENDS IN CLINICAL RADIATION ONCOLOGY
Date : May 20- 22 , 1982
Location: The Hospitality House , Williamsburg , Virginia
Tuition and Fees: $250.00
For physicians involved in the management of cancer. Lectures and small group sessions address
childhood cancer, Hodgkins Disease , Non-Hodgkin Lymphoma, prostate , cervix , ovarian , paranasal,
recto-sigmoid , breast, larnyx, and testicular carcinoma.

GYNECOLOGIC UROLOGY AND PELVIC SURGERY
Date: May 29- 31 , 1982
Location : The Homestead , Hot Springs , Virginia
Tuition and Fees : To be announced
Reviews basic and advanced concepts in gynecologic urology and pelvic surgery. Formal presentations
and small group sessions allow for didactic and direct exchange of information.

CARDIOLOGY
Date: June 18- 20, 1982
Location: The Hospitality House , Williamsburg, Virginia
Tuition and Fees: $230.00
For those who practice cardiology. Small group sessions highlight important information : deciding about
valvular heart surgery, hypertrophic myopathies , drug management of ventricular arrhythmias , intervention with acute myocardial infarct, and recent advances in treating heart failure.

PEDIATRICS AT THE BEACH
Date : August 4-7 , 1982
Location : Sheration Beach Inn , Virginia Beach , Virginia
Tuition and Fees: $235 .00
Allergy , immunology, dermatology, and orthopedics for the practicing pediatrician . Lectures and small
group sessions designed to provide clinical insight into topics such as persistent urticaria, steroids and
asthma, fungal dermatoses, and common orthopedic problems.

SUMMER RETREAT: PRACTICAL ISSUES IN PRIMARY CARE
Date: August 11-14, 1982
Location : Sheraton Beach Inn , Virginia Beach , Virginia
Tuition and Fees : $235.00
For the family physician, the general practitioner, the physician delivering primary care. Lectures and
discussion providing doctors with opportunities to discuss issues in cardiology, management of pain ,
antibiotics in medicine and surgery, and medical malpractice.
The Medical College of Virginia (MCV) is the State's major provider of continuing medical education
conferences and institutes. Two thousand physicians from across the United States participated in MCV
programs during 1980-81. Nationally known MCV faculty and distinguished guest faculty share medical
insights on the most recent and successful diagnostic and therapeutic techniques. Participants are
encouraged to share problem cases. Leisurely surroundings , informed practitioners , and involved faculty
blen d effectively to create pleasant and meaningful experiences in continued learning.
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The Gay Nineties: Oscar Wilde
Reconsidered
FREDERICK J. SPENCER, MD
Pro fessor and Chairman, Department of Preventive Medicine , Medical College of Virginia , Health
Sciences Division of Virginia Commonwealth University, Richmond, Virginia

Sex and hypocrisy have always been bedmates, but never more than in Victorian England. In the " Gay Nineties " promiscuity was
widely accepted in all social classes , although
the aristocracy hid its lust behind a strict code of
propriety. Country house parties catered to infidelities with the approval of the Prince of
Wal es , himself a notorious womanizer .
The sexual athleticism of His Royal Highness , Albert Edward, has been covered in innumerable books . 1 Protected from women by the
vigilance of his mother until he was 20 years
old, he was introduced to the delights of the bed
in Ireland by an actress/camp follower of the
Grenadier Guards. The bevy of mistresses that
followed resulted in one court case and several ·
minor scandals . His future queen , Alexandria ,
withstood his dalliances with dignity, finally
sending for Mrs Alice Keppel, his last and firmest mistress, when he was on his death bed, remarking at the same time that "He always loved
me the best ."
In 1890 , the word "gay " was used for
heterosexual relationships with prostitutes ,
today 's use not coming into effect until the
1 930s , and only into common use in the past
ten to 1 5 years. 2 The "Gay Lothario " of 1 7 0 3
was certainly no homosexual. 3 So the "Gay
Nineties '' were very gay indeed, in the old-fashioned sense of the word. As Mrs Patrick Campbell is supposed to have said , "You can do
what you like as long as you don't frighten the
horses.'' But sodomy was another matter. This
most despicable crime of all-the ''abominable
crime of buggery ' '-was the indictment
brought against Oscar Wilde in 1895. 4

Oscar Fingal O'Flahertie Wills Wilde was
born in Dublin, Ireland on 16 October 1854.
His father, Sir William Wilde , the son of a
doctor, was a pioneer otorhinolaryngologist and
opthalmologist , a combination of specialties
which existed well into the twentieth century .
Among Sir William 's innovations were angled
nasal forceps and "Wilde's Incision ," a deep
opening of the mastoid air cells in the treatment
of acute mastoiditis. 5 He was also a noted Irish
antiquary and archaeologist. Unprofessionally ,
his sexual promiscuity led to several illegitimate
children and to a prosecution for molesting a female patient of dubious virtue; she was
awarded % d in damages-the smallest possible sum!
Oscar Wilde's mother, known as Speranza , was an accomplished poet and the author of several revolutionary pamphlets , a sufficient reason for her nom-de-plume, even if
women authors had been socially acceptable in
the 1850s.6 Oscar was the second of Lady
Wilde's children , and his elder brother , William ,
later known as " Wuffalo Will ," became a notorious and intemperate man-about-town .7 It is said
that Oscar 's mother wanted a daughter and
showed her disappointment by dressing him in
girl 's clothes until the birth of her third child, a
daughter, Isola, when Oscar was three years
old. 8 Much has been made of a picture of Wilde
in a girl 's dress at the age of two , the inference being that it was a conditioning factor in
his homosexuality, but it is doubtful if it played a
significant part in his sexual development as this
mode of dressing boys was not uncommon in
Victorian Ireland .9
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After preliminary schooling , Oscar Wilde
went to Trinity College, Dublin and thence to
Oxford where he acquired two things : a firstclass degree-and syphilis from a local harlot
by the name of "Old Jess." The resultant
mercury therapy left him with blackened, carious teeth for the rest of his life. From Oxford he
went to London, where his flamboyant dress
and brilliant conversation brought him notoriety, soon enhanced by a more solid reputation
as an author of plays, prose, and poetry.
In January 1882 , Wilde came to North
America , landing in New York where he was besieged by a curious public and press . When
asked by customs officials if he had anything to
declare , he said, "Only my genius ." He
reached Richmond on 11 July , notice of his lecture appearing for the first time in the Richmond
Whig on 28 June 1882 , and announcing that
tickets priced at $1 .00 for seats in the dress
circle and front stalls and 50¢ elsewhere were
available from Ramos and Moses.
The report of the lecture in the Daily Dispatch of 12 July 1882 , under the headline ,
" HOW THE GREAT APOSTLE OF AESTHETICISM LOOKED ," is devoted more to Wilde 's
dress than to his words: " Mr Wilde was dressed
in the oft-described silk small clothes , including
knee-breeches , &t. , silk velvet surtout, old style ,
satin-lined . There was pending from his neck a
long array of white dimity corrugated into numerous ruffles and extending some distance
down the diaphragm . Mr. Wilde 's appearance
was greeted with slight applause . . . . His hair,
which was of brown texture , was parted in the
middle and worn in ringlets over ample shoulders suggesting Buffalo Bill , only the aesthete is
by no means so comely a specimen of manhood as the great Indian scout and prairie warrior."
The critic continued by noting , ''An allusion to beautiful women and their influence was
recognized ... as having a personal application
to that section of the fair sex present , and was
received with vociferous acclaim .''
On his return to England , Wilde continued
his career as a brilliant writer and critic , meeting
the cream of aristocratic London , including
James McNeill Whistler , the American expatriate painter . 10 Whistler 's reputation as a
conversationalist equaled Wilde's, and they became great friends . Wilde , however, extended
his criticism to art, and this enraged Whistler
68 /
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who , with some justification , considered that
Wilde's knowledge of painting did not qualify
him as an art critic. Their open hostility led to
the famous story of how Wilde, on hearing
Whistler make some particularly witty remark,
said, "Jimmy, I wish I'd said that." Whistler replied, " You will , Oscar, you will ."

The Gay 90s
In 1891 , Oscar Wilde , at the height of his
career, met Lord Alfred Douglas, son of the
Eighth Marquess of Queensberry . The
Marquess, familiarly known as " Q," is best
known for the Marquess of Queensberry's
Rules , which brought some decorum into the
prize ring of the day and remain the basis of
modern boxing refereeing. 11 Oscar and Lord Alfred , or "Bosie" as he was known , soon became close friends to the disgust of "Q," who
was better known as a bullying sportsman than
as a doting father . The Queensberrys were notorious for their sexual escapades , particularly
" Old Q," the Fourth Marquess , who , in his
eighties, erected a bow window in Piccadilly so
that he could ogle passing girls .
This family failing , however, did not lead
to " Q's" accepting Wilde 's advances to Lord
Alfred , and the Marquess, with one of his prize
fighters , went to Wilde 's house to order him to
leave his son alone . After some angry words ,
Wilde showed " Q" to the door, telling his servant that he was never to admit this " most infamous brute in London " to his house again .
Queensberry , in a frenzy , planned to ruin the
first night of Wilde's play, The Importance of
Being Earnest, but was prevented from entering
the theatre by a cordon of police, thoughtfully
recruited by Wilde .
Frustrated, "Q " stormed into the Albermarle Club and gave his card to the hall porter
with instructions that it be handed to Wilde
when he next came in; on the back of the card
was written , "For Oscar Wilde posing as somdomite. '' The usual explanation of the incorrect
spelling is that the enraged ''Q'' misspelt
"sodomite," but perhaps spelling was not his
strong point . Wilde received the card about two
weeks later and unwisely sued the Marquess of
Queensberry for criminal libel.
The trial attracted the greatest legal minds
of the day, and by brutal cross examination ,
" Q's" counsel showed that the libelous statement was almost certainly true. Wilde 's defend-

ing counsel declared his intention to withdraw
from the case, first in private to Wilde, and the
next day in court. The Marquess was immediately acquitted , and his lawyers referred the evidence adduced at the trial to the Director of
Public Prosecutions.
Wilde left the court at noon on the fifth of
April, 1895 and was arrested at 6:30 PM that
evening. There is no doubt that he could have
fled the country, and was indeed advised to do
so, but he vacillated helplessly, and the last
train for the continent left without him. At his
trial , the jury could not agree on a verdict, but
on retrial, he was convicted of committing "acts
of gross indecency '' and sentenced to two
years hard labour. In passing sentence, Mr Justice Wills said that it was the worst case he had
ever tried , accused Oscar Wilde of being " the
centre of a circle of extensive corruption of the
most hideous kind ," and added that he was
"expected to pass the severest sentence that
the law allows'' although it was ''totally inadequate for such a case as this ." 12
Broken in spirit and health upon leaving
prison, Wilde went to France and died there in
1900. The cause of his death has been attributed to neurosyphilis or to an intracranial suppuration from otitis media. He had sustained an
ear injury in prison with subsequent and recurrent drainage. 13 His bones were reinterred in the
famo us Pere-Lachaise Cemetery in Paris in
1909 .
In 1912, Jacob Epstein, then an avantgarde sculptor, was commissioned to create a
suitable tombstone for Oscar Wilde ; his response was to hew an immense winged sphinx
from a 20-ton block of Hopton Wood stone.
This was transported to Paris and placed
over Wilde's grave, but the nakedness of the
sphinx's genitals was considered indecent by
the Paris gendarmerie, who refused to let Epstein complete his work. 14 There is a story, perhaps apocryphal, that two English ladies were
so incensed by the tombstone's offending organs that they stoned them, some of the chips
ending up in the cemetery office as paperweights!
Oscar Wilde was bisexual, and his marriage in 1 884 was followed by the birth of two
sons within two years. No satisfactory explanation of his deviation has been given~ and
theories still abound to explain it, as indeed they
do for all homosexuality. Suffice it to say that in

the 1 890s-the decade of " decadence"-licence of all kinds was condoned by the followers of aestheticism, and Wilde, who was no
drinker or drug taker, suffered the penalty of
being branded with the most hei nous offence of
all in Victorian eyes. Had he ignored Oueensberry's action, he might well have continued his
career in peace , as did many of his " decadent "
colleagues , despite their excesses.
That Oscar Wilde has been forgiven by
society became evident in 1954 , the centenary
of his birth , when the London County Council
unveiled a plaque affixed to the wall of the
house he occupied at the time of his trials.
Appropriately, the ceremony was conducted
by Sir Compton Mackenzie, the flamboyant author, who once said , " All my life I've lived hand
to mouth. Damned good hand to mouth, mind
you .,, 15
What is to be learned from repeating the
tal e of Oscar Wilde? Perhaps only that the unusually harsh penalties imposed on homosexuals must now be redressed by an enlightened
humanity. Today, consenting homosexuals may
live together openly in Britain ; in this country ,
prosecutions of homosexual offenders have become rare , and as a recent Time essay said , " It
is true that America has a great deal to be
ashamed of in its treatment of homosexual citizens .... The best public policy toward homosexuals is no policy at all-no sodomy laws, no
special interventions pro or con. On matters of
consensual adult sex , the law is, or should be,
blind. '' 16
The words that Oscar Wilde wrote to Lord
Alfred Douglas from Reading Gaol could today
well apply to the world: " Perhaps I am chosen
to teach you something much more wonderful ,
the meaning of Sorrow , and its beauty ." 11
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Medicine in Retrospect

[The following is a transcript of an informal talk
by Ors Kinloch Nelson and Charles M. Caravati, presented in 1974 to the School of Medicine of the Medical College of Virginia, Health
Sciences Division of Virginia Commonwealth
University, Richmond, Virginia.]

Dr Caravati:
One of my first recollections while I was a
medical student was the severe pandemic of influenza of 1 91 8 and 191 9. There were in excess of a thousand patients at one time in the
John Marshall High School, which was used as
an emergency hospital. The death rate wasterrifically high ; the most serious complication was
empyema, but most of the deaths were apparently caused by betahemolytic streptococcus
infection superimposed upon the influenza
pneumonitis. The medical students acted as
orderlies in the temporary hospital.
If you went on the wards of St Phillips or
Memorial Hospital in those days, you would find
any number of cases of typhoid fever between
July and September; there was no therapy for it,
and in many patients it was fatal . Malaria was
common until the end of August. As people
went to the seashore, many of them developed
malaria.
In the winters, pneumococcal pneumonia
was a very common disease. All we really knew
about it was how to diagnose it. There was
nothing we could do for it except [to take] general measures and to comfort the family and ·
have a good nurse on the job. It is interesting to
recall that during the influenza epidemic, the
Richmond Health Department stated the only
worthwhile medicine was whiskey .
In 1934 a type specific serum came into
use, which was very effective for certain specific
types of pneumococcus. The health department
had /a typing station where we could have the
sputum typed promptly, but the severe reactions encountered [by the patients] kept a lot of

physicians from using it because of its potential
anaphylactic effect.
Childhood diseases were serious and
prevalent. The most fatal in those days was laryngeal diphtheria, and some of us were trained
to intubate for this complication . Interestingly
enough, laryngologists never did it. Dr Lipscomb, a general practitioner, was an expert intubator. He saved many lives by using laryngeal
tubes.
There were very few drugs that were of
any real help, although some newer ones were
being developed and used . For instance, Salvarsan and. bismuth were being used for syphilis. At that time , too, we were beginning to realize that specific vitamins helped some ·of the
disorders we were seeing , particularly those in
children .
When I was a freshman medical student,
Dr Joseph Goldberger of the Public Health Service came and talked to the profession about
pellagra and explained that a good general diet
and nicotinic acid would cure it. I remember
very well his making the statement that more
than 300 people had died of pellagra that year.
Then came one of the great breakthroughs in medicine--the discovery of insulin
by Banting and Best in Toronto j n 1922. This
was the first time, I believe, that a cooperative
therapeutic effort was made by the medical profession and a pharmaceutical manufacturer. Eli
Lilly co-produced the insulin for Banting and
Best, which was later distributed to doctors in
designated regions of the country by a physician in each region , who had to be provided
with the proper protocol for its use.
In Richmond we had to apply for insulin to
Dr Lester Newman, a pathologist in Washington , DC. I had come back to Richmond in 1924
to practice, and I had been here only a few
months when I went to Sheltering Arms Hospital
and saw a four-year old child in diabetic coma.
It was the second episode of coma she had
had, and I remember speaking to Dr Newman
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on the telephone and trying to persuade him to
send me insulin without a protocol.
Eventually he agreed and sent some on
the RF&P Railroad , and the drug was given to
this child the next day. Later, when she was
about 30 years of age, she walked into my office one day just to say hello and tell me she
was living in Cleveland. That was the first real
success in controlling chronic disease that I can
recall, and I think it is significant to remember
the way it was handled by the profession and
pharmaceutical industry.
In 1925 Minot and Murphy discovered
that people with pernicious anemia improved on
an adequate diet, particularly one with flesh
meat and liver. Practically every patient treated
in this way went into remission and stayed in remission indefinitely if they were kept on this
treatment . I think the original work was done in
the latter part of 1925, but we didn 't use it clinically until 1926 and 1927.
I recall one female with pernicious
anemia, who had been kept alive with frequent
transfusions, and the dietician in the hospital
ground up some pork liver and started feeding
the patient half a pound a day. She went into remission shortly after receiving this new diet and
died of a cerebral accident eight years later. It
was soon discovered that the active principle in
eliminating the anemia was in liver.
Dr William Branch Porter, chairman of the
Department of Medicine at MCV, had the Valentine Company of Richmond manufacture an extract from liver, and the company made the first
extract that was for sale in America . It was
called Valentine Extract E-29, and it was a very
effective treatment. It took about one ounce of
the oral extract each day to control the anemia.
The rest of the story, as you know, was the discovery of B-1 2 as the active principle.
Not long after this we found out that brucella abortus and tularemia, which were originally thought to be diseases in animals, could
cause human disease, and we began to diagnose a few cases in this area, though frankly
there were very few cases in Richmond or even
in Virginia.
Endocrinology was beginning to be talked
about at this time, and the active principle of the
parathyroid gland was isolated. Between 1932
and 1934 Barr, who was professor of medicine
at Barnes in St Louis, and later at Cornell, described the clinical symptoms of hyper-
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parathyroidism and how it could be cured by
the removal of the adenoma in the parathyroid
gland. He showed that after surgery the cystic
changes in the bones went away, and the biochemical changes all went back to normal. This
work led to the treatment of certain cases of hypoglycemia by the removal of a pancreatic adenoma.
In 1 93 7 ergotamine-tartrate was reported
by Lennox as effective treatment for migraine
headaches, and we thought this was a great
thing because previously there was nothing a
physician could do for these people except put
them to bed , pull down the shade, and let them
stay there, nauseated and vomiting , for three or
four days.
In Germany in 1 935, Domagk found that
certain sulfonamides were very effective against
betahemolytic streptococcal infections. In this
country in 1936, it was recognized by the profession as a powerful anti-infectious agent.
The first drug was called Prontosil , a sulphanilamide that came in the form of a red halfgram tablet. With the possible exception of
quinine for malaria and of Salvarsan , which was
used for the treatment of syphilis, this sulpha. nilamide was the only specific drug used to treat
infections.
I remember seeing a 36-year old man with
a temperature of 104° or 105 ° F with a membrane in his throat and cervical lymphadenopathy and betahemolytic streptoccus infection of
his throat, which two days later became a
bloodstream infection. At that time Prontosil had
just been developed, and it was given to this
man who had difficulty in swallowing the first
couple of tablets.
He stayed sick for another two days, but
in 48 hours his temperature began to come
down, his tachycardia disappeared , and he was
considerably better in five to seven days. In
those days we didn't repeat blood cultures, but
clinically he became well. After that, Sulphathiazole , Sulphadiazine, and Sulphapyridine
came into use, Sulphapyridine being an excellent drug for pneumococcal pneumonia.
Though penicillin was discovered by
Fleming in 1929 and subsequently purified by
Florey and Chain in Oxford, it was translated
into clinical usefulness by scientists at the North
Regional Laboratories in Peoria, Illinois. Penicillin was made available during World War II,
and its distribution was directed by Dr Chester

Keefer of Boston. In the beginning it was used
only for gram-positive infections.

Or Nelson:

What I am going to say is somewhat autobiographical. I came back here [to Richmond]
to practice medicine at the McGuire Clinic on
July 1, 1929, at a salary of $150 a month. In
October, 1929, the roof fell in! St Luke's Hospital usually had 85 to 90 patients. The cut-off
point was around 65 or 66, as I understood it;
at that level you came out about even . Anything
above that was nice, but anything below that
was real tough .
The hospital population dropped off almost immediately to around 20 where it stayed
for several years . Through the kindness of Dr
Stuart McGuire, the institution held together,
and my salary was gradually reduced to
$112 .50 a month. I never knew why I got the
50¢, but I never asked anyone.
Mr Roosevelt came into office and started
the WPA and the CWA and those other federal
agencies that created work , one result of which
was the building of the Lee Bridge. The number
of physicians applying for the opportunity to examine the workmen who would build the Lee
Bridge was out of this world . The man responsible for these funds was Dr Wyndham Blanton,
Sr, the present Dr Wyndham Blanton's father,
wh o was recognized for his general overall integrity, so he was given the task of deciding
wh o would examine these birds!
Well, I was one of the early applicants,
and it was finally decided that we would each
work a certain number of shifts. We examined
the workmen at the rate of 50¢ apiece . We
could examine ohe man in fifteen minutes '
across the street from here in the basement of
the City Hall Annex , which was recently pulled
down.
Shortly before this, the physicians of this
area began to realize that the best possible arrangement they could have was to work in
groups. I think the McGuire Clinic group was
one of the first to organize, and there was some
criticism of this because doctors thought they
should stand on their own feet and not associate with a group. This ied to the question of
whether a patient could "get a square deal" in
a group. It seemed to me then and now, that
there is no better doctor /patient relationship

than that in which the patient picks out his doctor for whatever reason .
There was one lady who was going to a
doctor whose capacity was certainly rather indifferent. I asked her why in the world she
picked out this fellow . She said he looked more
like a bulldog than any other doctor she 'd ever
seen. Well, on this basis he had her confidence,
so she 'd tell him her problems, which he attempted to take care of . She expected to pay,
and he expected her to pay, and you can 't beat
that . In my opihion there isn 't any other system
that will ever equal that , but we have to play it
the way it is.
There was interest about that time in the
care of the indigent of the City of Richmond,
and Dr B. Foster of the Health Department suggested that I take on the job as doctor to the
poorhouse . To tell you the truth, I didn't exactly
know where the poorhouse was, but I ended up
there working part time at $50 a month . Added
to the $112 .50 [I was already making at
McGuire Clinic] , this was a considerable increase, and things seemed to be getting better.
There used to be an idea that the physician had a certain responsibility to the poor.
Some physicians had office hours at certain
ti' mes of the week for those who could not pay
in the same office in which, at other times, they
saw those who could pay .
We seem to have shifted away from that
feeling of taking care of the overal.1population . It
has somehow become the responsibility of
somebody else to take care of those who cannot pay . It is interesting to remember that there
once seemed to be a shortage of patients. A
group opened an office with the idea of helping
out in an indigent area. Shortly, the patients
didn 't seem to be there , and they had to ciose
down. This was an odd circumstance.
After the second World War, I think the
most Striking thing that took place was the development of the "medical center. " The medical school had, of course, been well known for
many years , and everyone knew something
about the teaching of medical students and to
some degree [had knowledge of] the housestaff
and nurses.
There was the necessity for employing
faculty members to take care of many obligations besides direct patient care and teaching
residents and students. This was hard to get
across to people . All of these concerns have
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brought about full-time physicians who, in many
instances, have never really practiced medicine-have never really gotten down to the nitty
gritty. This makes it difficult for them to understand the problems of the practice of medicine ,
and, on the contrary, those in practice have difficulty in understanding the problems of the faculty members who are in ''the ivory tower .' '
These divisions have led to a lot of problems, but they are not new. If you go back in the
history of the Medical College, you will find
some of the most remarkable fights you ever
saw in your life _!hat_took place before the
1900s. In the meantime, it appeared to me
that the medical student and housestaff member were somehow divorced from the practice
of medicine and consequently were not "interested " in practicing medicine . Now, this is baloney because the statistics show something
like 90-odd percent of the graduates of this
school have gone on to practice medicine.
Back in 1950, Dr Sanger managed to get
some money to allow us to rotate our housestaff through community hospitals, and we sent
them to four or five-I think Eastern Shore ,
Franklin , Farmville, Fredericksburg, and Norfolk , but this created some problems . These
boys were, for the most part, married , which , as
you know , is one of the greatest changes to
take place in medical education .
When I was a student, nobody was married.
There was one fellow who was married-incidentally, his wife had a baby, which was the
biggest surprise all of us ever had. We were
senior medical students and saw this lady ·
everyday, and if you had asked me the day before she had the baby whether she was pregnant or not, I would have said no.
In any case , through Dr Sanger 's influence we began to try introducing the housestaff
and students to some of the actual practice situations that exist in this neighborhood. After
rotating the interns through the hospitals, we
started a Home Care program , for which we obtained money through the Commonwealth
Fund . The idea was for medical students to see
something that took place in actual life .
Unfortunately, this was not exactly actual
life. This was life of a sort , but many physicians
today never see patients such as those that
were seen in Home Care then . These were
people who lived in half a barrel over here on
the city dump and had no money and no any-
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thing. How they ate, lived or whatever, nobody
knew. You don 't see patients like that in your
practice-at least, I hope you don 't. Then we
put students out in the affiliated hospitals, very
much the same hospitals as we sent the interns
to 20 years ago , plus a few more.
There are a couple of other things that
stand out in my mind as developments over the
years . I remember one difference is that now if
you call a doctor, sometimes nobody answers
the telephone. This seems remarkable . If you
called a doctor in 1930, about four people
would answer the phone. Even today a ringing
telephone gives me the jitters because I'm not
sure whether it is somebody who really needs
something or somebody that I need . I cannot
imagine how it is possible to practice medicine
and have an office that [allows telephone calls
to go unanswered], but it can be done, and it is.
The second thing that bothers me is the
idea of telling everybody everything. I was
raised on the principle that the doctor knew
best, and the patient didn 't know anything , and
the better off he would be if he didn 't know any
more. I am not sure but what this is right . I think
this business of advising everybody of all the
details of all the problems that they have or may
have is really bad . I don 't know what you do
about it exactly, but I can tell you what I have
done about it.
I was called one night to see a man who
had , as far as I could see , a coronary thrombosis . So I went back to the office and got the
electrocardiogram machine which took three
leads-three, not twenty-three-and went
back to his house. According to the three leads
that ran out of the thing , it looked to me like he
had a coronary thrombosis. So I told him I had
to go back to the office to develop the film.
Well , this didn 't make much sense as it
was coming right out of the machine, but it
suited him all right , so I went back and developed the film , and while I was there I got a normal electrocardiogram. I went back [to his
house] , and he said, " How does that thing
look?" I said , " Boy , it looks fine to me. Here it
is. You want to see it?" He said, " Well , I don 't
know anything about those things ," and I said ,
" That doesn't make any difference. I'll show it
to you. "
So I pointed out the normal pulse waves
and ORST , and he started feeling better right
away. I didn 't do him any harm, I think , and

don 't see what good it would have done
for me to tell him how it did look by saying,
"Boy, you've got it!" Now, I do think you ought
to tell the patient 's wife or son or whoever is responsible.
Another thing that interests me is that I believe the AMA or somebody has decided that
we are short 50,000 doctors. I don't know how
they arrived at that figure ; there's some complicated calculation which shows that if you
graduate all the doctors who are graduating,
and all those who have died or are dying, and
none die un~xpectedly or in an epidemic, in
some unknown year in the future we will reach
the necessary number of doctors, whatever that
means . I think that 's " for the birds."
I think that in your lifetime, and hopefully
mine, we will have doctors coming out of our
ears. By the time the doctors now being graduated by medical schools, plus those who will
shortly begin to do so , plus the trained personnel now going on in various thing$ like physici ans' assistants , nurse practitioners , med-x ,
and so forth , we will have an excess of people
doing first-line medical care . It is a supply and
demand business , and I hope I live to see that.
1

Discussion
Question : Who is the greatest medical character
you remember in Richmond?
Dr Nelson :

I can think of one doctor I won 't name
who was always referred to as the '' cheerful
little cricket." To my knowledge he never
smiled in his life. Oddly enough , his patients
seemed to love this very sad approach ; everything was going downhill all the time, but he had
plenty of practice-plenty.
I recall another who was a great crier. In
other words, if anybody was very ill or somebody died , and members of the family were
weeping, he was the greatest weeper there .
Tears ran down his cheeks like a waterfall. He
was very popular .

surgery. As far as we know, he did it well. He
was the best toastmaster in the area , and every
medical meeting was enlivened by him . He
would always tell a story, and he always had
dozens of them.
Question : Dr Nelson, how about your service in

the 45th?
Or Nelson:

Well , I'm glad you mentioned that. I went
into the 45th General Hospital as a major. Why I
wasn 't made a higher rank I ni:.iver could understand . Dr Thompson, I believe, was a lieutenant , and in no time at all he became a captain ,
but I was still a major. Shortly after that, he became a major; I was still a major. Shortly after
that, I left the army. I figured I'd done all I could.
I couldn 't get promoted, so forget it. What Dr
Thompson is talking about is that I became ill
due to my arduous service and was sent home
on a stretcher . As I embarked at Naples, the
band came down to see all the poor souls who
were going home, and among them were 16
pregnant nurses.
One of them had just had a baby--cutest
baby you ever saw. One nurse had arthritis, and
she had a lot of x-rays so nobody would accuse
her of the problem that the other girls had .
Incidentally, this was the first boat from
Naples that came straight back to the States.
Prior to this time, wounded and sick troops were
sent from Naples to Africa. Sometimes the doctor in Africa was kind of an eager beaver and
wanted everybody to serve , so he'd send them
back to the front in Naples. Well, they didn't like
that , so they worked out a boat to take them
straight back to the States.
The chief doctor on this boat was an obstetrician, and he had been in the army for I
don't know how long. He hadn't seen a pregnant lady since he got into the army, and we
presented him with 16 cases. He nearly had a
fit; he was examining people all the way home .
Dr Caravati:

Dr Carava ti:

Dr W. T. Oppenheimer was one of the real
interesting medical personages of his time. He
was President of the Richmond Academy of
Medicine in 1900, and he lived about 45 more
years . He was an excellent general practitioner ,
if you want to use that term, and he did general

I thought it might be worthwhile just commenting that during World War I many of you
may not know the Medical College of Virginia
was also the 45th General Hospital under [the
direction of] Dr Stuart McGuire, and Dr Nelson's
father was one of the prominent members of the
staff in 1918. The hospital was in action during
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the period of some of the hardest fighting
around the Argonne. The history was written by
Dr Joseph Geisinger, who was a uroloQist in
town, and it is well worth reading .
Question : Will you comment on the merger of
the two school~ of medicine in Richmond?
Or Caravati:

You'll have to remember that geographically the two schools were only two city blocks
apart which, of course, should have never
been . All the faculty were part time, and the faculty members in the · two schools practically
never spoke to each other. They had very
strong feelings about this, but perhaps the competition made for good medicine because they
tried to outdo each other when they made scientific presentations.
In 1 91 O the Flexner Commission found
that they were gradufiting too many physicians
in the $late and recommended the merger of
the Medical College of Virginia and the University Coll~ge bf Medicine. After that, there was a
fight about twice a week, as I understand it.
However, the merger was accomplished in
1 91 3 through the efforts of many outstanding
people led by Dr Stuart McGuire, Dr George .
Ben Johnston, Dr Christopher Tompkins, and
Mr Eppa Hunton . Ors McGuire and Johnston
were not friends; only as far as their interest in
medical education did they get together.
There were a lot of stories about individual
physicians and their behavior at meetings. Dr
Daniel Coleman is said to have come to a
meeting with a pistol on his hip, and no one
knew whether he had real bullets in it or not.
He stood on a chair and said, "I am not as big
as the rest of you, but look here."

right over here on Clay Street. Now it is adjacent
to Richmond Memorial Hospital. In days gone
by, every doctor thought it a privilege to be able
to take care of patients at Sheltering Arms. I
know we all thought it was a great thing to be on
the visiting service, and also to teach the
nurses; we really did think it was a privilege to
do all thi~ . No doctor ever received a penny for
his services, nor did any patient pay for his or
her care.
Question: Have you s~en anything in medical
education that has changed, ot is educating doctors about the same as when you were in
school?
Dr Nelson:

Everything has changed. I was thinking
the other day about Dr W. B. Porter. Dr Porter
was a very handsome person, and he was very
concerned about his appearance; he always
had on a spotless white coat and a little flower
in his buttonhole. He had the idea that he ought .
to look like a doctor-whatever that means.
Were he to see some of our present campus
candidates, I'm sure he'd be revolving wherever
he is.
The most remarkable change I have seen
has been in the last four or five years. Everyone
seems to be going into primary medical care,
which I think is a very sall.jtary move. It's hard
for me to tell, you see, because I was raised as
a doctor. My earliest recollection is over here in
the old Memorial Hospital with my father, sitting
in the waiting room while he went to see a patient or two . I can remember the horse he had
named Phyllis. Every now and then Phyllis
would take it into her head to go home. When
we would come out of wherever we were, there
was no horse.

Or Nelson:

The father of Mr Eppa Hunton was really
the catalyst between the warring groups and
brought them together in the consolidation of
the Medical College of Virginia in 1 91 3 more
than anyone else.
Question : Do you have any further comments

about the care of the indigent patient?
Dr Caravati:

Well, one dramatic example is Sheltering
Arms Hospital. Sheltering Arms was for years
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Dr Caravati:

One development that has been interesting to me is that now you can't find a doctor
to come to your home. Most patients can be
transported to an emergency room in one of the
hospitals. Probably 50 percent of the patients
seen there are not true emergencies. Because
of well qualified physicians who are full time,
good care is administered in an excellent setting. This makes many house calls unnecessary, and I believe this practice will grow rapidly. To me it is a really interesting evolution of

the practice of medicine, and I think it is going
to continue to grow.

talk to the wife about the husband , you just call
her into the bathroom and shut the door, and
nobody else will come in there.

Or Nelson:

I would like to put in a plug for house calls.
If you have an occasion in your practice to see a
patient in the home, I would recommend it.
There is no better place you can get to know
them as well , and it has always struck me as
odd that when you get into the home, about the
only private spot is the bathroom. If you want to

Or Spencer:

Thank you very much indeed, Dr Nelson
and Dr Caravati. You have shown that history
doesn 't have to be dull and uninteresting, and I
am delighted that you could tell us about your
50 years of practice. Thank you very much
again .

Or. Nelson is Dean Emeritus and Dr. Caravati, Professor of Medicine Emeritus. Medical College of
Virginia, Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia.
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Recent Advances in Cancer Chemotherapy
ROBERT B . DIASIO , MD
Associate Professor of Medicine and Pharmacology, Medical College of Virginia, Health Sciences
Division of Virginia Commonwealth University, Richmond, Virginia

The present status of cancer chemotherapy can be reviewed in light of selected basic
principles with an acknowledgement of the role
of established chemotherapeutic agents. Four
chemotherapeutic agents recently approved for
clinical use and their impact when used in combination regimens should be examined . Several
important concepts influencing chemotherapy
in the 1980s include the use of chemotherapy
in the adjuvant setting, the use of hormonal receptor data in planning therapy, and the use of
in vitro tests on tumor specimens to predict tumor sensitivity to cancer chemotherapy drugs
(prior to administration of these potentially toxic
drugs to a particular patient) . Lastly the reader is
cautioned about the potential of long-term complications with certain chemotherapy agents ,
especially in those patients who have had complete or extended partial remissions.

Review
The modern era of cancer chemotherapy
began approximately 40 years ago when nitrogen mustard , a derivative of the mustard gases
used in the World Wars, was demonstrated to
cause regression of lymphomatous tumors initially in studies involving mice and later man.
Since that time a variety of chemicals and natural products have been synthesized (or isolated)
and subjected to various screening programs in
an attempt to identify potential clinically-effective drugs. Today there are approximately 30
drugs that have been approved and deemed
valuable in the treatment of various human cancers. 1 These agents can be categorized into six
major classes (Table 1 ).
The development of these diverse agents
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which effect various critical biochemical steps
or processes has occurred during a period in
which there have been rapid and significant
gains in our understanding of the molecular biology of the cell. Concomitantly , there has been
an increased understanding of tumor cell biology which has markedly influenced the way
cancer chemotherapy drugs are used today .
Cell kinetic studies in animal models have demonstrated that a single malignant cell can multiply within a host animal to eventually kill the
host . Thus curative therapeutic approaches
must aim to eradicate every malignant cell .
Studies with anticancer agents in animal models
have shown that chemotherapy kills cells in a
first-order kinetic manner, ie , with each treatment a constant percentage (rather than a constant number) of cells is killed . These generally
accepted "principles" have provided support
for the aggressiveness now used in many of the
multiagent chemotherapy regimens and have
formed the basis for adjuvant and maintenance
chemotherapy .2
Multiagent , or combination chemotherapy , the major approach used in advanced cancer today, has been influenced by a better comprehension of the cell cycle . Thus it is
recognized that certain drugs act on cells only
in a specific phase of the cell cycle (the life
cycle through which a cell passes from its origin
when formed from the mother cell to the point at
which it in turn divides into daughter cells) while
other drugs are non-cycle specific, being able
to affect cells regardless of where they are in
the cell cycle, including cells not actively replicating . The recognition of this concept has
been utilized in designing effective combination
regimens which aim at affecting cells in different
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phases of the cell cycle to obtain the maximum
therapeutic effect.
The success of chemotherapy in the management of human cancer can be seen in Tables 2 and 3. 2 Table 2 demonstrates that in at
least seven tumor types, chemotherapy now offers either cure or at the very least a significant
prolongation of life. While actual cure has not
been achievable for the five tumors listed in
Table 3, there nevertheless has been a demonstrated increased survival and palliation. For the
remaining tumor types not listed, including the
relatively frequent cancers such as carcinoma
of the lung and large bowel , cure and palliation
are less likely at present. With the development
of new agents, it is hoped that more effective
combination regimens will be created to improve survival in these currently less responsive
tumors as well.

TABLE 1
Classification of Cancer Chemotherapy Agents
Alkylating Agents
Mechlorethamine (Mustargen)
Cyclophosphamide (Cytoxan)
Chlorambucil (Leukeran)
Melphalan (Alkeran)
Triethylenethiophosphoramide (thiotepa)
Nitrosoureas
(BCNU or Carmustine)
(CCNU or Lomustine)
(5-(3 ,3-Dimethyl-1-triazene)-imidazole-4carboxam ide)
(Dacarbazine or DTIC)
Anti metabolites
Methotrexate
5-Fluorouracil (Fluorouracil , Adrucil)
Cytosine arabinoside (ara-C or cytosar)
6-mercaptopurine (Purinethol)
6-thioguanine (thioguanine)
Antibiotic
Dactiomycin (actinomycin D. (Cosmergen))
Mithromycin (Mithracin)
Doxorubicin (Adriamycin)
Daunorubicin (Daunomycin)
Mitomycin C (Mutamycin)
Bleomycin (Blenoxane)
Natural Products
Vinblastine (Velban)
Vincristine (Oncovin)
L-Asparaginase (E.lspar)
Miscellaneous Agents
o,p '-DDD (Mitotane (Lysodren))
Hydroxyurea (Hydrea)
Procarbazine (Matulane)
Cis-platinum diamine dichloride (Cisplatin, Platinol)
Hormones
Estrogens
Androgens
Progestational Steroids
Adrenal Steroids
Antiestrogen tamoxifen citrate (Nolvadex)

Update
Over the past several years there have
been four new agents introduced clinically that
are now not only approved for non-investigational use but also occupy important roles in
cancer chemotherapy already. The increasing
use of all four drugs necessitates a basic understanding of them by every physician participating in the care of a particular cancer patient.
Doxorublcln (Adrlamycln}
Perhaps the most important new agent is
Adriamycin . This drug and the closely related
drug Daunorubicin (Daunomycin) are anthracyclene derivatives obtained as fermentation
products from Streptomyces (Fig 1 ). These
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Type of Cancer
Gestational trophoblastic tumors

Burkitt 's tumor
Testicular tumors (nonseminoma)

Wilms ' tumor
Neuroblastoma
Acute lymphoblastic leukemia

Hodgkin's disease , stage lllB and IV

TABLE 2
Cure or Increased Survival
Chemotherapy
Methotrexate , dactinomycin,
vinblastine
Cyclophosphamide (many others)
Dactinomycin,
Methotrexate chlorambucil,
Bleomycin , Cis-platinum diamine
dichloride
Dactinomycin plus vincristine with
surgery and radiotherapy
Cyclophosphamide with surgery
and /or radiotherapy
Daunorubicin, prednisone , vincristine,
6-mercaptopurine, Methotrexate,
BCNU
MOPP, ABVD

Results

70% cured
50% cured
70-80% respond; 2-3% cured

30-40% cured
5% cured
90% remission ; 70% survive beyond
5 years
70% respond; 40% survive beyond
5 years

(Note: Adapted from I H Krakoff , Cancer Chemotherapeutic Agents , Ca-A Cancer Journal of Clinicians, 27, 1977 , 132.)
(By Permission)

drugs are classified as antibiotic cancer chemotherapy agents.
The mechanism of action of both drugs is
believed to be via inhibition of DNA synthesis.
These agents are known to interact with DNA,
eventually intercalating into the nucleic acid helix leading to uncoiling of the DNA and inhibiting
both RNA and DNA synthesis. Both agents are
maximally effective during the S phase of the
cell cycle , but inhibition can occur at all stages
of the cell cycle, particularly at higher concentrations .3
The pharmacology of these drugs is still
somewhat incomplete. At present they are used
only intravenously. The major site of metabolism
is in the liver by both soluble and microsomal
enzymes. Less than 1 0% of the drug is excreted in the urine. Because of the importance
of liver metabolism, the dose of Adriamycin is
reduced in the presence of hepatic dysfunction .
No· drug adjustments are made for renal dysfunction . The total dose should not exceed
550-600 mg/M 2 . 2 · 3
Both drugs have similar side effects and
toxicities including: 1) gastrointestinal (nausea ,
vomiting, diarrhea, and stomatitis); 2) hematologic (leukopenia with a nadir at 1 0-1 5 days,
and thrombocytopenia); 3) dermatologic (alopecia, local phlebitis and necrosis if extravasated); 4) cardiac (by far the most serious toxicity with these drugs is manifested as
congestive heart failure due to a diffuse cardiomyopathy).
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The major indications for Daunorubicin
(Daunomycin) have been in acute granulocytic,
and in lymphocytic , leukemia. In contrast ,
Doxorubicin (Adriamycin) has been active not
only in leukemia but also in bladder cancer,
breast cancer , bronchiogenic cancer, Hodgkin
and non-Hodgkin lymphoma , thyroid cancer
and sarcomas in general.
Bleomycin (Blenoxane)

Bleomycin, also of the antibiotic class of
chemotherapy agents isolated from Streptomyces, is actually a mixture of several similar
polypeptides, each having a molecular weight
of approximately 1500. The A2 peptide is the
major compound present in the commercial
preparation and is believed to be the active
component (Fig 2).
The mechanism of action of Bleomycin
appears to be by scission of double-stranded
DNA, resulting in fragmentation of DNA, in turn
causing inhibition of DNA synthesis . This drug
appears to block cells at the G2 /M interphase
of the cell cycle.
The pharmacology of this drug in vivo has
been limited by the fact that the drug is a mixture of several compounds . Following administration, it disappears rapidly from the plasma
with an estimated half life of 1 5-60 minutes.
Since the dq..1g is known to be excreted primarily
via the kidneys, the dose should be reduced in
the presence of renal dysfunction . Bleomycin is ·
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Bleomycin A

Fig. 2.

degraded mainly by the action of animonopeptidase which is present in tumor cells,
liver and kidney. It is absent from the skin and
lungs, two tissues which are particularly susceptible to damage from this drug. Bleomycin is administered either intravenously, intramuscularly, or subcutaneously. 2 •3
As noted above, Bleomycin toxicity includes skin toxicity (such as hyperpigmentation,
thickening, ulceration, rash, alopecia, or nail
changes) and pulmonary toxicity. This last severe toxic finding may be present as pneumonitis with dyspnea, r~les and infiltrate progress-

Type of Cancer
Prostate carcinoma
Breast carcinoma

Chronic lymphocytic leukemia
Lymphosarcoma
Acute myeloblastic leukemia

ing to fibrosis. The occurrence of toxicity need
not be related to the cumulative dose although it
is more frequent with a total dose greater than
250 units/M 2 or a single dose greater than 25
units/M 2 . The risk is increased particularly in individuals more than 50 years old who may have
prior lung disease or may have previously been
treated with radiation therapy. Pulmonary function tests have not been of value in predicting
pulmonary toxicity. A cumulative dose of 400
units is the accepted maximum dose. Since the
drug is a polypeptide, a potential side effect
with this agent is anaphylaxis. Fever and chills

TABLE 3
Palliation and Prolongation of Life
Results
Chemotherapy
70% respond with some prolongation
Estrogens, castration, cyclophosof life
phamide
60-80% respond with probable
Androgens, estrogens, alkylating
prolongation of life
agents, 5-fluorouracil, vincristine,
prednisone, Methotrexate,
Adriamycin
50% respond with probable prolongaPrednisone, alkylating agents
tion of Me
50% respond with probable
Prednisone, alkylating agents
prolongation of lifa
65% remission with prolongation
Cytosine arabinoside and
of life
thioguanine

(Note: Adapted from IH Krakoff, Cancer Chemotherapeutic Agents, Ca-A Cancer Journal of Clinicians, 27, 1977, 132.)

(By Permission)
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cis-Diamminedichloroplatinum
Fig. 3.

occur in 20-30% of patients . The possibility of
hypersensitivity is particularly a problem in lymphoma. Nausea and vomiting may also occur
with administration of Bleomycin . One toxic
manifestation notably absent with this chemotherapeutic agent is the lack of hematologic toxicity making this drug especially appealing for
combination chemotherapy.
The major indications for Bleomycin have
been in lymphomas (Hodgkin and non-Hodgkin}, testicular tumors, and squamous cell carcinoma of the head and neck. Other indications
are less clear at this time .

Cis-Diamminedichloroplatlnum (Cis-platinum, Platinol)
This agent is a heavy metal coordination
complex of platinum containing two ammonia
groups and two chlorines in the Cis conformation (Fig 3) . It is listed as a random synthetic type of chemotherapeutic drug . The
mechanism of action appears to be through inhibition of DNA synthesis thought to result from
both interstrand and intrastrand crosslinks in
DNA. It appears to be cycle non-specific.
Cis-platinum is administered in an intravenous solution usually in an infusion from 1 5
minutes to eight hours. Following administration, plasma levels of the drug show a biphasic
pattern of decay with an initial half life of 2 5 to
50 minutes and a terminal half life of 58 to 72
hours. Studies of distribution have demonstrated the greatest uptake in the excretory organs, ovary, and uterus. More than 90% of the
platinum following administration is protein
bound. Cis-platinum is excreted mainly via the
urine. This drug should be used with caution or
even withheld if renal dysfunction occurs with a
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creatinine clearance of <60 ml/min . An attempt has been made to minimize renal toxicity
secondary to Cis-platinum administration by
hydrating the patient prior to drug receipt, giving
diuretics and infusing chemotherapy slowly.
The renal toxicity appears to be dose related. Close follow-up of BUN, creatinine, and
uric acid , and particularly creatinine clearance
is advisable. Other side effects include ototoxicity, relatively frequent nausea and vomiting,
leukopenia, thrombocytopenia, and anemia .
Anaphylactic reactions have been described in
no more than 1% of the patients given this
drug. Peripheral neuropathies and loss of taste
are less common side effects. 4 This drug appears to be active in testicular tumors, ovarian
cancer, bladder cancer, and head and neck
cancer.

Tamoxifen Citrate (Nolvadex)
Tamoxifen is a synthetic non-steroidal triphenylethylene derivative that has been demonstrated to have potent anti-estrogen activity in
several mammalian species . It is classified as a
hormonal type of chemotherapy agent (Fig 4 ).
The mechanism of action appears to involve inhibition of estrogen binding to cyctoplasmic estrogen receptors present in sensitive cells such
as breast cancer. It is believed that following
binding to the receptor, estradiol-estrogen receptor formation is blocked. Since. this receptor
is necessary for activation of certain nucleic
acid processes, the hormonal response of these
cells is blocked .
This drug is given orally in 1 Omg tablets.
Following oral administration , peak levels occur
within four to seven hours. The initial half life is
estimated to be from seven to 1 4 hours. Pro-

DIASIO: RECENT ADVANCES IN CANCER CHEMOTHERAPY

Tamoxif en
Fig. 4.

longed blood levels may therefore occur. This is
thought to be due to concentration and excretion into the bile tract with reabsorption through
the enterohepatic circulation.
Toxicity due to antiestrogenic actions include hot flashes, vaginal bleeding, menstrual
irregularities, and pruritis vulvae. Non-specific
gastrointestinal side effects have been described such as nausea, vomiting and distaste
for food . Other toxic manifestations may include
fluid retention, hypocalcemia, ahd dizziness.5
The major indication at present is in palliative treatment of advanced metastatic breast
carCinoma. The use of this drug in estrogen-receptor positive premenopausal women with
breast cancer is currently being evaluated by
the National Surgical Adjuvant Breast Project.
New Combinations

The addition of these new agents has
made possible new combinations taking into
account not only the principle of cell cycle and
cell kinetics suggested earlier, but also permitting modification of toxicity since many of these
new agents have toxicity different from many of
the standard agents in chemotherapy. For example, Bleomycin and Tamoxifen have essentially no hematologic toxicity and are attractive
to use in combination with agents that might
cause marked hematologic toxicity. Two particularly interesting new combinations include the
ABVD regimen (Adriamycin, Bleomycin, Vinblastine and 5-(3 ,3-Dimethyl-1-triazene)~imida
zole-4-carboxamide) used in Hodgkin disease
and the Cis-platinum-Bleomycin-Vinblastine
combination used in testicular cancer.6
The ABVD combination has been shown
to be approximately equally active to the MOPP
c ombination (Mechlorethamine + Oncovin
+prednisone+procarbazine) used in the treatment of advanced Hodgkin disease. More importantly, there appears to be little cross resistance of the ABVD regimen with the MOPP
combination making possible a suitable alternative treatment for MOPP failures. The combined
use of Bleomycin and Adriamycin has also been
shown to be active in some recent combinations
used in non-Hodgkin lymphomas as well. 7
In testicular cancers the contribution of
these new agents (Bleomycin and particularly
Cis-platinum) is even more impressive. While
several active agents have been available for

many years including Methotrexate, Actinomycin D, and Mithramycin , the percentage of
complete remissions was consistently 30% or
less with no prolonged survivals. The combination of Cis-platinum-Vinblastine-Bleomycin has
resulted in complete remission rates of 70% or
greater with an increased percentage of prolonged survivors.8 The evolution of chemotherapy in the treatment of testicular cancer with
first the addition of Bleomycin and later the addition of platinum illustrates the point made earlier that as new agents are introduced in combination with other effective agents, there is hope
that still more effective combinations will be
found in the treatment of other cancers as well.
Adjuvant Chemotherapy
Adjuvant chemotherapy is usually defined
as the use of chemotherapy together with surgery and / or radiotherapy. As suggested earlier,
cell kinetics provide a rationale for the use of
adjuvant chemotherapy. Following removal of a
tumor mass and a curative resection , the cell
number should be reduced dramatically. When
the cell number is relatively low, tumor cells are
more likely to be actively growing and dividing .
Since most chemotherapeutic drugs will kill
cancer cells actively "in phase " in the cell
cycle, it should follow that the smaller the tumor
mass, the larger the growth fraction and the
more likely the cells are to respond to cytotoxic
drugs. The fact that only one cell is needed to
theoretically kill the host, and the fact that
chemotherapeutic drugs kill in a first-order kinetic manner, further supports the rationale for
chemotherapy in the adjuvant setting . A number
of experimental studies using mouse and rat tumor models have substantiated the value of adjuvant chemotherapy in prolonging survival. 9
Clinical trials have now demonstrated a
definite role for adjuvant chemotherapy in at
least delaying the occurrence of metastases in
premenopausal patients with breast cancer. It is
still somewhat early to evaluate the overall effect on survival, although it does not appear to
be as promising as originally hoped. Two regimens have been used in extensive adjuvant
studies in breast cancer in this country and
abroad. The American study has utilized the alkylating agent L-phenylalanine mustard, while
the European study from Italy has utilized the
combination of Cyclophosphamide, Methotrexate and 5-fluorouracil. Both studies have dem-
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onstrated a definite role in premenopausal cancer, although the role in _postmenopausal
cancer is somewhat less clear. 1 0
On osteogenic sarcoma there has been a
dampening of the original enthusiasm for adjuvant chemotherapy. The initial regimens used
during the past five years have included the use
of Adriamycin with and without other agents
and the use of high-dose Methotrexate. In these
studies there has been the suggestion that
again metastases may be delayed; but in this
case it appears much less likely that any overall
improvement of survival has resulted. 9
For other tumor types the role of adjuvant
chemotherapy . at present remains much less
clear. There is, however, the hope that with
newer agents resulting in more effective combinations, there will be increased effectiveness of
these drugs used early in the course of the disease with the anticipation that not only the onset
of metastatic lesions will be delayed but also
that survival time will be prolonged .
Receptor Status
Over the past several years there has
been widespread acceptance by the medical
and surgical community of the importance of
obtaining breast tumor specimens at the time of
surgery for assessmerit of estrogen as well as
possibly other hormonal receptors. 11 The estrogen receptor assay has been shown to have a
positive correlation greater than 65% with response to hormonal therapy in several large
studies recently completed . Fwrthermore, patients with estrogen ~receptor negative tumors
appear not to respond to hormonal therapy . The
most important impact of this receptor data is
that approximately a third Of all breast patients
with metastasis are estimated not to respond to
hormonal therapy. With the use of the hormonal
-receptor assays, patients who are estrogen-receptor negative may be spared ineffective therapy and may be begwn on more effective cytotoxic chemotherapy at an earlier point.
Less clear is the importance of estrogenreceptor negative status in premenopausal
patients. Recently it has been suggested in a
retrospective study conducted at the National
Cancer Institute that estrogen-receptor negative
patients may actually respond better to chemotherapy than estrogen-receptor positive
patients. This study, however, has been contradicted by yet another retrospective study. At
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present time prospective studies are needed
to clarify this hypothesis, and no recommendations can be made. 12

Prediction of Drug Response
For many years there has been the hope
that one could test tumor cells, much as one
tests bacteria cultured from an infected patient,
thereby making a more rational choice of the
agent or agents to be used. To some extent this
approach has already been adopted in breast
cancer where the presence or absence of estro- gen receptors in the tumor specimen from a
particular patient may determine whether hormonal therapy will be used. Recently a new
method was d~monstrated which permits tumor
cells, obtained from specimens at the time of
surgery, to be cultured so that drugs may be
tested for possible effect. While only a limited
number of cases have been studied at the present time , data in multiple myeloma and ovarian
cancers suggest that the possibility exists that
indeed a predictive test may be possible , 13
thereby at the very least preventing the use of
ineffective cytotoxic drugs and possibly determining effective drugs that may be used in the
treatment of the individual patient. Again research will be conducted in the 1980s which
will further clarify the usefulness of this new
method. 14
Long-Term Effects of Chemotherapy
While the immediate and idiosyncratic effects of the various chemotherapeutic agents
have been well known , it is now clear that some
of these drugs, particularly the alkylating agents
and those drugs that intercalate into DNA, may
result in the development of secondary neoplasms. These usually occur four to five years
after the initial chemotherapy has been completed . 15 The implication is that the very patients
- who have been ''cured'' by chemotherapy have
then gone on to develop neoplasms secondary
to the initial chemotherapy. This has now been
seen in an increasing number of chemoresponsive tumors ; eg with the use of alkylating
agents in multiple myeloma or with alkylating
agents with or without radiotherapy in Hodgkin
disease.
The effects of radiotherapy have long
been known to be associated with secondary
neoplasms so that patients receiving radiotherapy and chemotherapy with agents which
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interfere with the DNA structure may be especially at risk. With the development of more effective combinations, it is hoped that some of
the agents responsible for these catastrophic
toxicities may be removed and replaced by
' 'non-carcinogenic'' drugs.
Lastly, there will be a need to review the
use of certain potentially ''carcinogenic'' agents
in adjuvant regimens, especially in those patients who may indeed have been cured by surgery. With more experience it is hoped that the
more toxic agents may be removed from these
combinations as well.
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Cancer is the number two killer in the
United States and will probably account for
some 400 ,000 deaths in 1982 . The lung has
now achieved the dubious distinction of being
the most common site of cancer in men and
causes the most deaths. Cancer of the colon
and rectum is the second most common cancer
in both males and females combined, whereas
carcinoma of the breast and uterus predominate in women.
The incidence of most cancers has been
rising rather slowly over the past several decades for reasons that are not clear, possibly because of increasing contamination of our environment by chemical carcinogens, air pollution,
and prescription drugs. In males lung cancer
has dwarfed the incidence of most of the other
tumors ; even in females there is an ominous recent sharp angling of the curve upward . Carcinoma of the stomach and carcinoma of the cervix have markedly declined during the past
several years, but the reason for this is unclear.
Perhaps the decline may be related to some
dietary factor which has been eliminated due to
better techniques for preserving or preparing
meat.
It is useful to examine the anticipated fiveyear cancer survival rates for specific sites
taken from the Surveillance Epidemiology End
Results Group of the National Cancer Institute .
Many localized cancers, particulary those of the
bladder, breast , colon , larynx, prostate and
uterus, show prolonged survival times. The notable exception is the lung with a five-year survival of only 23%, even if the tumor is localized
at the time of surgery. The American Cancer
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Society purports to indicate that this means tumors should be detected earlier. An alternative
explanation is that those tumors which remain
localized are biologically less malignant and
grow more slowly, and therefore have a greater
likelihood of being found at a time when they
have not yet spread.
· What is not emphasized is that for prostatic neoplasms and lung cancer , probably 8085% of the tumors are disseminated when first
discovered, so that the localized cancers are in
the distinct minority. Once a tumor has been
disseminated, the chances for prolonging survival are greatly diminished .
During the past five years there have been
no substantially new modalities of therapy . In
some areas our surgical techniques are already
extremely refined while in other areas they continue to evolve , as in the currently expanding
use of microsurgery in pituitary, pineal , ocular,
and laryngeal tumors . There has been a proliferation of endoscopists, and it is now a rare endobronchial, colonic, or jejunal lesion that manages to escape direct visual inspection through
the endoscope befpre it is removed .
Substantial advances have been made in
diagnostic radiology, particularly in the areas of
CT scanning and ultrasound . Radiotherapeutic
techniques have gradually evolved as well.
Treatment planning is better because of newer
computer-simulated models. The high-voltage
linear accelerator and the use of newer heavy
particles, such as the neutron and photon
beams , have also given a higher therapeutic index in specific problems.
The cumulative impact of these refine-

ments in surgery, radiology, and chemotherapy
has been substantial. For example, in radiotherapy there has been great improvement in
survival for those who have tumors that are both
radiosensitive and tend to be localized . There is
little question that we have markedly improved
the therapeutic index in retinoblastoma, testicular carcinoma, Hodgkin disease, and have improved the situation in head and neck cancer,
as well as prostate, bladder, ovary, and tonsil
cancer.
More striking is that a number of cancers,
particulary congenital trophoblastic tumors, Burkitt lymphoma, testicular neoplasms, Wilms
tumor, and neuroblastoma are now being cured
routinely by chemotherapy. Hodgkin disease
has been heavily affected by appropriately used
radiation therapy and chemotherapy, sometimes in combination. Survival of patients with
Hodgkin disease in 1979 is probably greater
than 50% for all tumors. Chemotherapy is also
generally agreed to be useful for palliation of
prostatic carcinoma and breast carcinoma as
well as chronic lymphocytic leukemia, lymphosarcoma, and acute myeloblastic leukemia.
We have not changed survival times of patients with the more common solid tumors to
any extent despite the progress we have made
in controlling the fluid tumors of leukemia and
lymphoma. Little progress has been made in
prolonging survival of patients with solid organ
tumors, particularly those of the lung, colon,
and genitourinary tract which are the most common and which far outnumber leukemias and
lymphomas. Nevertheless, a great deal of progress has been made during the past decade.
We have learned much about the biological behavior of human tumors, some from animal experimentation and some from carefully
designed cooperative clinical trials. There are
two important concepts which have had considerable impact: first, the concept of micrometastases and their relationship to tumor burden ,
particularly in breast cancer; and second, differences in biologic aggressiveness among histologically-similar types of cancer as exemplified
by Hodgkin disease.
With respect to the concept of total tumor
burden and micrometastases, it should first be
stressed that all tumors, when discovered, are
actually in a fairly late stage of their growth . If
we assume that a tumor begins as a single cell
and continues doubling and growing ex-

ponentially, it has already divided approximately
30 times to reach a size of about 1 0° or 1 09
cells and a weight of about one gram. A one-cm
tumor nodule is probably at the limit of detection
either by palpation or x-ray.
Treatment may accomplish any of several
goals. An effective treatment may shrink the tumor drastically, perhaps by a factor of a thousand, but unless every cell is destroyed , it is almost certain that the tumor will recur. If the
recurrent tumor tends to follow the same kinetics as the earlier tumor, its rate of growth will be
the same. This is usually the case except in the
case of metastatic tumors; such tumors usually
grow faster. In general, the more substantial the
response, the longer the survival.
In some instances effective treatment,
such as hormonal therapy, may drive the tumor
into a state of dormancy or quiescence, so that
its rate of growth is changed, but at some later
point when it resumes autonomous growth , it
will again grow at a rate similar to the rate it exhibited initially or even faster.
Many chemotherapists have spoken of
eradication of the last tumor cell. We now know
that this is somewhat naive and may perhaps
apply to one or two tumors in which most all the
cells are actively growing and are susceptible to
a chemotherapeutic agent. In the most common
solid tumors such as those of the lung, breast,
and colon , only a portion of the cells are in
cycle and are susceptible to chemotherapy at
any one time.
It is likely that many tumors continually
shed cells into the circulation, and the cells that
are shed must be counted in the total tumor burden. There was an experiment which was performed in mice in which an implanted mammary
carcinoma was allowed to grow to the size of
700 mg. At that time surgery was performed,
and all visible tumor was excised. Nevertheless,
it was clear that there must have been micrometastases at sites distant from the resection because with large tumors essentially no mice remained tumor free one month after surgery.
There is a striking parallelism between this
experiment and a similar study performed in humans where the tumor burden was simply measured by the number of positive lymph nodes
found during surgery in patients with breast carcinoma. As the number of positive nodes increased , the ten-year survival of these patients
fell drastically. A number of surgeons claim that
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patients with higher numbers of positive lymph
nodes do poorly because the nodes act as a
secondary focus of disease and that more extensive operations should be performed.
If this thesis were correct, then there
should be clearly demonstrable differences between patients that had different types of operations. The newer operation that is now being
performed is a simple or total mastectomy in
which just the breast is removed, but the contents of the axilla are not taken (they may be
biopsied but are not removed), and the pectoralis muscle is also preserved. This is to be
compared with a standard radical mastectomy
in which the entire contents of the axilla are removed together with the pectoralis muscle,
leaving only the intercostal muscles and the ribs
after mastectomy.
After five years the National Surgical Adjuvant Breast Protocol Groups have shown no difference in survival among almost 1 ,000 patients who underwent different types of
mastectomy. This would affirm that the reason
for failure of breast carcinoma treatment is due
to distant metastases which are not visible at
the time of surgery. This concept has had an
enormous impact on the area of breast cancer
because it has led to trials of adjuvant chemotherapy which have, in fact, greatly improved
survival where surgery could not.
In Hogkin disease we have a similar situation but with one additional complicating factor.
First, we do know that in Hodgkin disease the
total body burden of the disease does bear a
close relationship to prognosis. Early in the
treatment of Hodgkin disease, many of the observers at Stanford and other institutions concluded that most Hodgkin disease spread by
contiguity and that the disease essentially could
be cured if radiotherapy could be applied to all
the involved fields plus an additional margin of
safety around the field. Thus, Stage I could be
treated by radiotherapy to the axilla and the mediastinum.
An additional important prognostic factor
in Hodgkin disease is the histologic type of the
disease. Four current histologic classifications
are recognized : lymphocytic predominance,
nodular sclerosis, mixed cellularity, and lymphoid depletion . In this progression the last type
has the most Reed-Sternberg cells, the least
lymphocytes, and the worst prognosis, no matter what the stage. Each of these histologic pre-
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sentations is closely associated with a specific
stage of the disease; for example, lymphoid depletion is extremely rare in Stage I and is most
found in Stage Ill or IV. On the other hand, lymphocytic predominance is usually found as
Stage I or Stage II. Although there is some overlap between histologic patterns of the disease,
in the main the histologic patterns tend to persist for long periods of time.
It is beginning to appear that Hodgkin disease may consist of at least four separate clinical entities, each of which pursues a different
course and for which different management
strategies are indicated. For Hodgkin sarcoma,
which tends to disseminate rapidly and probably does not spread by contiguity, localized radiotherapy would be useless and systemic chemotherapy would be the more effective agent.
Similarly, for lymphocytic predominance, chemotherapy would probably represent too much
treatment. An important corollary has been that
the presence of systemic symptoms indicates
that the disease is aggressive and probably will
also require systemic treatment . Thus, even if
the disease is Stage II during intensive investigation but systemic symptoms are present, the
recurrence rate after radiotherapy only is high
so that chemotherapy should be considered
even at that early stage.
There are other examples of tumors of different biologic aggressiveness. It is easy to recall the difference in aggressiveness, growth
rate and prognosis in patients with estrogen-receptor positive and estrogen-receptor negative
breast cancer. In malignant melanoma as well,
it has become apparent that certain types of
melanoma, particularly the lentigo maligna or
the superficial spreading melanoma, are much
less virulent than the nodular melanoma. This
undoubtedly will be important at a later time in
treatment, but as yet no effective treatment regimen has been designed for any of these stages.
Another important topic for which great interest has been generated during the past decade is that of the possibility of immunotherapy,
that is to say, that of immunizing the patient
against his own tumor. Unfortunately, this treatment will also have to await the future because
there is no firm evidence that immunizing patients with their own tumor in any way has altered survival or produced regression of the disease on its own. When used in combination with
chemotherapy, most controlled studies have not

indicated that there is any additional benefit of
adding immunotherapy, although the work is
not yet completed. One of the important dividends of immunotherapeutic research has been
the notion that there are certain antigens on the
surfaces of tumor cells which may be important
in diagnosis and detection.
The carcinoembryonic antigen (CEA) is a
specific antigen which is represented on the
surface of colonic tumors and also on the surface of the fetal colon as well. The tum9r sheds
CEA into the serum, and this can be detected
by radioimmunoassay . Whereas CEA levels
have not been found to be particularly useful in
the detection and screening of coionic carcinoma, they have been valuable for following the
course of the patient after surgery. Typically,
normal patients do not have CEA levels above
five nanograms per ml; colon cancer patients
. may have much higher levels2 If resection is

successful and complete, the levels fall rapidly
after operation . In 30~40% of cases, the CEA
rises several months before recurrence is clinically detectable.
In acute myeloblastic leukemia we have
been carrying out similar experiments at this institution in conjunction With the University of Toronto, and we have been performing tests on
bone marrow of leukemia patients in remission
to determine whether we mjght predict relapse
at an earlier time. Some of our data on 43 patients will soon be published in the New England
Journal of Medicine.
This suggests that tests can be devised
which will pick up impending relapse in patients
with myeloblastic leukemia approximately four
to five months before the tumor appears in the
bone marrow. We hope to exploit this fact by
applying reinduction chemotherapy at an earlier
stage.
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INTRODUCTION
Colorectal carcinoma accounts for the
majority of all gastrointestinal cancers and is the
second leading site of cancer, excluding skin
cancers, in overall incidence in the United
States. 1 Cancer of the stomach, although decreasing in frequency, is still an important cause
of morbidity and mortality. Unfortunately, data
from large numbers of patients such as can be
found in Cancer Patient Survival Report No. 5
show only very modest increases in survival for
patients with th~se diseases in recent years. 2
Gastric Carcinoma
Most patients who develop gastric cancer
have regional or distant disease at diagnosis.
The presence of regional nodal involvement is
almost synonymous with incurability since virtually all these patients are either non-resectable
at the time;i of operation or rapidly develop systemic recurrences. Any improvement in treatment results would be expected to be produced
by chemotherapy or immunotherapy rather than
from localized forms 9f treatment.
Fortunately, gastric carcinoma is relatively
responsive to chemotherapeutic treatment, and
at least four drugs have now been identified as
active in treatment of this condition, namely 5fluorouracil (5-FU), Adriamycin, mitomycin-C,
and semustine (methyl-CCNU). Although semustine is the nitrosourea that has been most
extensively used in the chemotherapy of gastrointestinal neoplasms, it is still an investigational
drug and therefore is not always conveniently
available. Other nitrosoureas that are on the
market are probably similar in activity.
Percentage of response and increase in
survival with single-drug therapy have been
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modest, and for this reason the drugs have
been combined into a variety of multiple-drug
regimens . Most of the possible two and threedrug combinations of the four active drugs have
been tried.
Table 1 shows response rates and survival figures for some of the most extensively
tested combinations. The combination of 5-FU
and semustine was one of the first advocated as
being superior to 5-FU alone in the treatment of
gastric carcinoma. More recently 5-FU plus
Adriamycin plus mitomycin-C (FAM) combinations have become more popular. The FAM
regimen was initially reported to have a 50% response rate in gastric carcinoma. The most recent update of over 60 patients indicates that
the response rate is holding at approximately
43%. 3
The FAM regimen (Table 2) is a well-tolerated treatment which gives partial or complete
responses in about one half of the patients and
benefits other patients by stabilizing the disease, resulting in prolonged survival for the population of treated patients. Quality of survival for
many is good, and it is not uncommon to see
responses lasting for over one year.
One problem with the treatment is cumulative marrow toxicity which is attributed to
the mitomycin-C in the regimen . This tends to
limit the treatment that can be given after the
first few cycles. The cycles of treatment are similar to other day-1 , day-8 treatments given every
eight weeks.
Other combinations of these drugs which
utilize different doses and regimens have also
been tried. Two of these used at the Sloan Kettering Institute known as MIFA I and MIFA II con~
firm that these drugs in combination are effec-
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TABLE 1
Combinations Used in Treatment of Gastric Carcinoma

5-FLUOROURACIL + Semustihe
5-FLUOROURACIL + ADRIAMYCIN + MITOMYCIN-C
5-FLUOROURACIL + ADRIAMYCIN + Semustine
5-FLUOROURACIL + MITOMYCIN-C
ADRIAMYCIN + MITOMYCIN-C

tive in the treatment of gastric cancer .4 Table 1
indicates treatment results of these and other
combination treatments for gastric cancer. The
median survival of patients with untreated advanced gastric carcinoma is four months or
about 1 7 weeks from diagnosis . Since the figures in Table 1 show the survival in weeks from
the time of treatment rather than diagnosis for
the entire population of treated patients, not just
the responders, one can see that a doubling of
the survival time for the better combination is
achievable.
Dr Charles Moertel from the Mayo Clinic
has recently analyzed data combined from several cooperative groups . Using a statistical
model, he concluded that 5-FU and Adriamycin
contribute most to the treatment of gastric cancer. 5 This is a combination that has not received
extensive use, and the projected value of the
treatment needs confirmation in a large clinical
trial.

Colorectal Carcinoma
Although there have been a number of attempts to improve results in treatment of colorectal cancer, most of these have been futile or
have achieved only very modest success. The
surgical treatment of colorectal cancer has
been standard for several decades, and although some recent studies indicate that pre-

TABLE 2
FAM Regimen
DAY 1
F
A
M

DAY8
F

DAY 29

DAY 36

F
A

F

F = 5-Fluorouracil
600 mg/M 2
A= Adriamycin
30 mg/M 2
M = Mitomycin-C
1 O mg/M 2
Cycles of treatment are repeated every eight weeks.

Response Rate

Med. Survival Weeks

9-45%
21-43%
36%

24-34
22-30

17-25

17

operative ahd postoperative radiation therapy
given adjuvantly in high-risk patients would be
beneficial , particularly in patients with carcinoma of the rectum , these suggestions have not
met with widespread acceptance.
Five-fluorouracil has been a standard
treatment for colorectal cancer for 20 years ,
and one might summarize the clinical experience of a number of investigators' attempts to
improve results by manipulating the 5-FU dose,
schedule, or route of administration by simply
stating that no schedule of treatment has been
definitely shown to be superior to any other.6
The most common schedules used have been
daily intravenous. treatments for five days repeated at five-week intervals or one intravenous
treatment administered weekly .
Administered orally , 5-FU gives response
rates similar to the intravenous treatments of the
drug . However, Moertel 7 has reported that the
duration of response is shorter with the oral
form of treatment. Absorption is erratic, averaging about 50% . Because of these facts and because no oral form of treatment has been marketed, use of this drug by this route of
administration has not gained wide acceptance.
Response rates with 5-FU in colorectal
carcinoma average approximately 20%. Two
forms of therapy which have a response rate
above 1 0% are the nitrosoureas and mitomycin-C . Other drugs have either had limited use
in colorectal cancer or have given response
rates of 1 0% or less, leaving only a few drugs
that have a significant response rate in this disease.
A number of combinations have been devised for the treatment of colorectal carcinoma,
the more extensively tested combinations
being : 5-FU with semustine, mitomycin-C or hydroxyurea; 5-FU plus semustine plus vincristine ;
and 5-FU plus semustine plus dacarbazine . Response rates for the combinations were initially
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reported to exceed the results of 5-FU alone.
The combination of 5-FU, semustine and vincristine has been said to have response rates in
the range of 35 to 40% by at least three different groups. 8 •9 · 10 However, as additional studies
and survival data are reported, the superiority of
this combination over 5-FU alone has not been
confirmed. 6
Median survival for patients after proof of
incurability is approximately 30 to 32 weeks
with 5-FU alone, anq for the combinations the
survival has be.en in the same range . Consequently, the current consensus is that no
combination of drugs for the treatment of colorectal carcinoma has proved to be superior to 5FU alone. At this time other combinations are
being tried which, it is hoped , will yield results
surpassing those with only 5·-FU.
There is controversy regarding whether or
not 5-FU alone increases survival in patients
with colorectal carcinoma. To my knowledge,
no prospective randomized trials have been
done comparing 5-FU with no treatment in patients with advanced disease. Used many years
ago for the treatment of advanced colorectal
cancer, 5-FU was shown to yield responses and
was felt to be beneficial , not only in achieving
these responses but also in extenc;jing the life of
the patient. No Qne has since been willing to
compare it to no treatment.
One can easily demonstrate that 5-FU responders live longer than non-responders. Additionally, retrospective analysis indicates that
5-FU produces a modest increase in median
survival in a population of treated patients.
Moertel' s own data1 1 demonstrated that 5-FU
treated patients live longer throughout the entire
survival curve than matched historical controls.
This difference was discounted by Moertel who
stated that there is no evidence showing that 5FU prolongs survival , attributing the difference
to patient selection . This is only an opinion, and
different interpretations are possible.
A number of surgical adjuvant trials have
been conducted in patients with colon and rectal carcinomas. One of the earliest studies utilized thiotepa or fluorodeoxyuridine (FUdR) after
surgery. This particular study showed no effect.
However, it is of interest that these patients, followed over a decade, had no increase in carcinogenicity or other 1<;3.te toxicity which could be
ascribed to those treatments. 12 More recentiy a
number of studies have been done utilizing 5-
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FU in adjuvant treatment. In the non-randomized studies using historical controls, 5-FU was
reported to produce a beneficial effect 13 · 14 ; in
the randomized studies the 5-FU , in all cases,
produced a slight prolongation of disea$e-free
interval and survival in the treated group. 15 - 19
lnitialiy, the difference was judged not to be statistically significant; however, a recent statistical
analysis using cumulative results involving
larger patient numbers resulted in the conclusion that there is a statistically significant improvement, at least for some subsets of 5-FUtreated patients in the adjuvant setting. Results
of these studies are still pending .
In an article in the Annals of Internal Medicine,20 Ors Weiss and Devita stated that at the
present time whether or not a patient receives
adjuvant chemotherapy for colorectal carcinoma is a decision that needs to be individualized for each patient. This is primarily because the results of 5-FU have been marginal at
best, and the potential benefits of therapy may
be overridden by a variety of other factors: disease stage (patients with Duke 's 82 or C stage
lesions, eg, extension through the muscular
layer and / or invoived nodes are customarily
treated); age of the patient; histologic grade of
the tumor; economic factors ; and convenience
of travel to the treatment center for the patient.
Following a trial of adjuvant treatment, the decision to continue treatment should be based on
the patient's tolerance tempered by the knowledge of limited survival benefit .

Other Gas\rointestinal Tumors
There are three uncommon types of gastrointestinal malignancies, all of which show significant response rates to treatment with chemotherapy.
Leiomyosarcomas are found in the stomach and in the bowel . Recurrent or metastatic
tumors respond to treatment with Adriamycin in
approximately 30% of cases, and if combined
with dacarbazine, the response rate may be
1 0% higher. The treatment for metastatic
leiomyosarcomas of the bowel is the same as
for other metastatic sarcomas.
Lymphomas also occur in the gastrointestinal tract, and although their natural history
may be somewhat different from those originating els~where, the chemotherapeutic treatment
is basically similar. Where the histology predicts
a favorable outcome, treatment would probably
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consist of cyclophosphamide plus vincristine
plus prednisone (COP) therapy and the unfavorable ones treated in addition with Adriamycin
and possibly with Bleomycin.
Carcinoid tumors are also responsive to
chemotherapeutic treatment. About one third of
these patients with advanced disease show objective responses to treatments with 5-FU and
streptozotocin in combination . More recently
Adriamycin has been used as a single agent.
Treatment for this condition is still very much in
a stage of evolution .

Other Advances
The biologic marker known as carcinoembryonic antigen (CEA) which has been developed for clinical use in the last decade, ~as
contributed materially to our ability to stage and
follow patients with colorectal carcinoma. The
initial hope was that the test would be useful as
a diagnostic and screening tool. It has not
proved to be very useful for this purpose. However, it has been found to be beneficial as a
prognostic indicator. Patients with high levels of
CEA prior to surgery will not do as well as patients with normal levels. It can also be utilized
to assess adequacy of treatment or to evaluate
disease recurrence and treatment response. It
has been suggested that CEA-producing tumors are inherently more likely to metastasize
and are less controllable by the body's immune
processes . This biological difference, if confirmed , will undoubtedly influence future treatment strategies .
Table 3 presents data taken from a study
where 2, 3 7 2 patients of an unselected population were screened for malignancy using CEA
values .2 1 Seventy-three of these patients were
TABLE 3
Use of CEA in Screening an Unselected Population21
2372 people followed 5 years
87% False Positive 64% False Negative
CEA LEVEL
< 5 ng / ml
:?:5 ng / ml
Developed a
CEA related Cancer

16

11*

Never developed
Cancer

2000+

62

25

73
(3% of total population)
• two others were found to have incidental cancers not
related to CEA evaluation.

found to have elevated CEA levels above 5 ng /
ml. Workup of these 73 patients resulted in the
finding of malignancy in only 11 patients . Nine
had a CEA-related malignancy and two had an
incidental malignancy. The false-positive rate ,
therefore, was calculated at 87% .
More disturbing than even the high falsepositive rate was the fact that 1 6 patients who
were CEA-negative developed a CEA-associated cancer during the follow-up period for a
false-negative rate of 64% . Only 3% of the
2, 3 7 2 patients had elevated CEA levels which
is consistent with the fact that 95% of a normal
population are known to have CEA below 2. 5
ng / ml. (In this population , 97% had the CEA
level below 5 ng / ml.) The low incidence of cancer in this population of 2 ,3 7 2 resu lted in the
high false-negative percentage . CEA testing
may play a role in screening certain high-risk
populations , but it is not suitable as a screening
mechanism for carcinoma of the colon in unselected populations .
It was originally thought that CEA would
be specific for colon carcinoma since the antigen was obtained from fetal colonic ti ssue .
However, it was soon found that it is non-specific for colon carcinoma, being elevated in a
variety of other malignancies including breast,
lung , pancreas, stomach and bladder carcinomas, and in other malignancies. CEA is also
elevated in patients with liver disease, pancreatic cysts, gastrointestinal polyps and other benign conditions. The CEA is not specific for a
particular primary site and is not even as specific as one would like for malignancy.
With the understanding of certain characteristics of biologic markers shown in Table 4,
CEA tests can be used quite advantageously for
a number of purposes . In general , biologic
markers are non-specific for histologic types of
neoplasms and often are not even specific for
malignancy. The specificity and sensitivity tend
to be inversely related. By developing a more
sensitive assay, more positive results will be obtained in patients with non-malignant conditions
or with tumor types other than those anticipated. In contrast , if normal levels are drawn at
a higher concentration , the test is more specific .
For example, most patients with CEA over 10
ng/ml will have a malignancy.22 The percentage of patients with positive markers increases
with the stage of the disease. Reports of CEA
elevation in the 9 0% range are applicable only
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TABLE 4
Some Characteristics of Biologic Markers
1 . In general biologic markers are non-specific for a
histologic type of neoplasm and often are not even specific
for malignancy.
2. Sensitivity and specificity tend to be inversely related.
3. The percentage of patients with positive markers
increases with stage of disease.
4. Not all patients develop positive markers.
5. Marker status is not a dependent variable in relatipn to
staging .

to patients with advanced colorectal carcinoma.
The figure is much lower for patients with localized or regional disease only.
Not all patients develop positive markers.
Only those patients with certain phenotypic cancer cell expressions will show marker elevation.
Other patients having histologically-similar tumors will never be marker positive. Therefore, it
is futile to attempt to manipulate a test to give
results 1 00% of the time or to look for new
markers that will do this.
The percentage of CEA positivity in patients with colonic cancer was initially reported
in excess of 90%. Later the percentage fell, the
reason being that initially patients with advanced disease were tested , and in the later series more patients with earlier stages of disease
were tested. 2 3 The percentage of CEA elevation
directly correlates with the stage of disease;
however, it is not a dependent variable, meaning that the distribution of CEA positives in patients of various stages has a tendency toward
randomness. In general, CEA and other biologic markers are not dependent variables in relation to the stage of disease or any other
known prognostic factor. This means that prognostication is improved by considering marker
values along with stage, grade of tumor and
other standard prognostic indicators.
CEA is also useful in following colorectal
patients for recurrence. The majority of patients
who are found to have recurrences will have
shown at least one CEA elevation greater than
2 .5 ng/ml more than three months before documentation of recurrence. One study 24 showed
54% of the patients having this marker positive
(>2 .5 ng/ml) more than three months prior to
the documentation of recurrence. If a higher
positive value (5 ng/ml) is used, 41 % will have
an elevation three months before clinical tumor
recurrence . An additional number of patients
will have markers positive for three months or

less prior to recurrence. The percentage of patients who show elevated CEA prior to recurrence of colon cancer is higher than in rectal
cancer. (Table 5).
In colon cancer only 14% are never elevated prior to documentation of recurrence
compared to 32% for rectal cancer. While this
looks quite good as a tool for predicting recurrences, it has to be tempered by the fact that
matched controls also have a high percentage
of at least one elevated CEA value . The
matched controls were patients with the same
age, the same disease, and treatment, who had
not had a recurrence during periods of equal
follow-up. Some of these patients will eventually
turn out to have a recurrence because it is
known that the CEA can be elevated for as long
as several years prior to recurrence. Some of
these patients have random increases in CEA
value; others have benign causes of the elevation.
It is known that patients who receive blood
products at the time of their surgery sometimes
develop CEA elevations that plateau and later
decrease25 secondary to hepatitis or undetermined factors in the absence of acute or
chronic liver disease. The problem in following
these patients is to separate those who have
random elevations or benign conditions from
those who have a recurrence of malignancy. In
order to distinguish those with random elevations, a CEA nomogram has been developed to
indicate when values are statistically increased.
Nomograms are published in the literature,26 · 27
but to be valid , each laboratory should construct its own based on the precision of its test.
While the nomogram is useful in differentiating
patients who have a random increase from
those with a true increase in CEA levels, repeating the value several times helps in making this
differentiation .
It is important to make a diagnosis of recurrence earlier using CEA elevations. Some of
these patients may be candidates for second
surgery; others will be candidates for radiation
therapy or chemotherapy. In considering possible patients for second surgery, it is necessary
to separate those patients who are going to
have an operable malignancy from those who
have random fluctuation of the CEA , benign
conditions, and inoperable lesions. Using the
nomogram, one can distinguish most random
fluctuations . Benign conditions tend to be
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TABLE 5
Percentage of Patients With
Established Tumor Recurrence Who Exhibit
CEA Elevations 24
Primary
Tumor
Site
COLON
RECTUM
COMBINED

>2.5 ng/ml
>3 mos before
recurrence

>5 ng/ml
>3 mos before
recurrence

>2.5 ng/ml
<3 mos before
recurrence

>5 ng / ml
<3 mos before
recurrence

58
42
54

45
31
41

28
26
29

26
32
28

nomogram positive as are both operable and inoperable malignancies . The operable malignancies and random fluctuations would not be
expected to have elevated liver enzymes. The
degree of CEA elevation helps to discern the
operable and inoperable malignancies. High
elevations correlate with metastatic disease and
more specifically with liver metastases.
To determine operable cases one looks
for patients with minimal elevations of CEA. In
one series the mean elevation in the operable
patients was 6.5 ng/ml compared to 15 .5 ng/
ml in those who had inoperable malignancy. 28
Additional information can be gained by looking
at the character of the rise. If a benign condition
exists, the CEA tends to plateau at levels usually less than 1 0 ng/ml. For any type of malignant condition, an exponential rise occurs ; the
slope of the rise for those who are operable is
less than that for the inoperable ones. The value
is probably in the range of 0.5 ng/ml/mo or
less for operable cancers and >1 ng/ml/mo
for inoperable patients.29

Never
elevated
14
32

17

A factor to be considered in the decision
for reoperability is the interval between surgery
and observed CEA elevation. The benign causes
of the CEA elevations occur earlier after surgery
than the operable malignancies. 2 1 Any CEA elevations that occur early are more likely to be associated with inoperability. If they are caused by
tumor, they probably are rising at a more rapid
rate than those that occur later. Patients whose
CEA elevations occur more than five months after surgery are more likely to be eligible for reexploration . These factors are summarized in
Table 6.
It is important to stress that the decision
regarding reoperation is not based on just the
CEA level. A careful determination must be
made that the patient does not have clinical
metastatic disease by obtaining a chest x-ray,
liver scan, serum chemistries, and other appropriate tests such as sonography, abdominal CT
scan, and liver biopsy if other tests are negative . Careful monitoring and testing will exclude
five sixths of the patients for consideration for

TABLE 6
Differential Diagnosis of CEA Elevation

Nomogram

Liver
Enzymes

Random
Fluctuation

- or±

-

Benign
Condition

+

+

+

-

Cause of CEA
Elevation

Operable
Malignancy
Inoperable
Malignancy

Often

Often

++

+

Degree of
Elevation
Depends on
Baseline Value
Usually
<1 Ong/ml
Mean
6.5 ng/ml
mean
15.5ng/ml

Character
of Rise

Time of
Occurrence
Post-Resection
Random

Not
Verifiable
Non
Exponential
(Plateau)
Exponential
Slope
<1 ng/ml/mo
Exponential
Slope
> 1 ng/ml/mo

Median Time
<5mo.

)

Median Time
>5mo.

WAMPLER: RECENT ADVANCES IN GASTROINTESTINAL CANCER /

95

"second-look" surgery. Of the remaining one
sixth, the resectability rate may be as high as
30%. 30 Increasing the percentage of patients
operated on will decrease the resectability percentage . The cure rate for the patients who are
resected a second time is not known.
A practical strategy for following patients
with colorectal cancer with CEA assays is presented. Preoperative levels should be obtained
for establishing a base line and serve as a prognostic indicator. The test should be repeated
postoperatively. Two weeks after surgery is
both convenient and appropriate; however, if
the CEA level has not returned to normal , the
test should be repeated.
Apparently not all CEA values return to
normal promptly. If they remain elevated, it is
important to establish a base line for nomogram
analysis . Subsequently, values are obtained
every two months for the early detection of recurrence . After one year the test could be run
less frequently. If a significant elevation is encountered outside the normal nomogram range ,
the test is repeated serially, two or three times,
to verify elevation and determine, if possible,
the character of the rise. Concurrently, the patient is evaluated carefully for metastatic disease. Selected patients may be candidates for
surgery.
In patients who have developed metastatic disease, CEA can be used for evaluation
of chemotherapeutic or radiotherapeutic response. The CEA appears to be more correlated with tumor burden if its value is below 1 00
ng/ml. While this correlation is sometimes erratic, it is the most valuable tool available in patients who do not have measurable disease.

CONCLUSION
Chemotherapy has produced significant
improvement in treatment results for gastric carcinoma, but to date only minimal improvement
has been achieved for colorectal carcinoma.
Earlier application of radiation therapy, specifically preoperative and postoperative radiation
therapy, particularly for patients with carcinoma
of the rectum, is sufficiently attractive for further
study.
The primary area of improvement for patients with colorectal carcinoma has been in our
ability to assess the status of the disease and in
our beginning understanding of the biologic differences in patients with the disease . Ultraso96 /

nography and CT scanning are relatively new
procedures whose effect on the overall problem
remains to be assessed . Carcinoembryonic antigen testing is clearly an important advance,
and there is every indication that other useful
markers will be developed.
The net effect of all these developments is
the increased ability to select patients accurately for given treatments and to follow treatment results more precisely. It is known from
previous experience that in those diseases in
which the assessment of results is difficult,
progress has been slow. Therefore , it is anticipated that more rapid improvements in treatments in the coming years will ultimately be reflected in the overall survival statistics of these
diseases.
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Breast cancer comprises approximately
13 .9% of all cases of malignancy in both sexes
and 19% in women, in whom it is the commonest form of cancer . 1 The American Cancer Society estimates that 11 0,000 women developed
breast cancer in 1981 , and some 3 7 , 1 00
deaths from the disease occurred. ~ The fiveyear survival rate has been improving over the
past 40 years as shown in Table 1 1 , but patients remain in risk of recurrence indefinitely,
and survival for ten years is generally accepted
as the minimal time period necessary to establish the validity of new therapies.
Data from the first study of the National
Surgical Adjuvant Breast and Bowel Project
(NSABP) are shown in Table 2 and indicate that
the majority of women with breast cancer ultimately succump to the di$ease.3 Thus, although
only 1 0% of cases present with metastatic disease (an additional 5% predictably have very
rapid progression : inflammatory carcinoma, extensive local or regional disease), over half of
those undergoing mastectomy will develop recurrence within ten years .
The identification of women with either adverse or favorable prognostic features modifies
these figures considerably . Among the important favorable variables are : attainment of
menopausal status for at least five years ; in-

creasing age; primary tumors two cm in diameter or less; absence of regional node involvement ; estrogen and progesterone receptor
positivity and, for estrogen receptors at least ,
absolute amount of receptor; delay between initial presentation and recurrence ; skin or nodal
local recurrence as opposed to visceral metastasis; and perhaps most important, an overall
less aggressive biological character of the tumor.
Adverse prognostic features include : a
clinical picture of inflammatory carcinoma; concurrent pregnancy; liver metastasis; multiple visceral metastases at presentation ; brain, meningeal, epidural involvement, or spinal cord
compression secondary to vertebral collapse ;
lymphangitic pulmonary spread; absence of estrogen and , possibly, progesterone receptor;
failure of previous therapy for systemic disease;
and inability to withstand the toxicities associated with chemotherapy or hormonal therapy .
An excellent review of all phases of breast cancer has recently been published .5
I intend to concentrate on four areas in
greater detail : 1) the usefulness of receptor assays in predicting the response to therapy ; 2)
chemotherapy of advanced metastatic disease;
3) adjuvant chemotherapy following surgery; 4)
the usefulness of antiestrogens in hormonallyresponsive disease.

Supported in part by Grant Number CA 25045
awarded by the National Cancer Institute and CA 15492
awarded through the National Bladder Cancer Project by
the National Cancer Institute, DHEW,
Correspondence and reprint requests to Dr Wade K.
Smith , Box 162 , Medical College of Virginia, Richmond, Virginia 23298 .

Receptor Assays
Steroid hormones are known to act by
crossing the cell membrane where they bind to
specific cytoplasmic receptors . The receptorsteroid complex is activated and translocates to
the nucleus where it interacts with chromatin.
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TABLE 1
Five-Year Survival Rates In Breast Cancer
1940-1949
1953-1959
1960-1964
1965-1969

TABLE 3
Objective Response to Endocrine Therapy
No. Responding /
No.
Evaluable

53%
60%
62%
64%

(Note: Adapted from Cutler SJ, Myers, MH, Green SB:
Trends in survival rates of patients with cancer. N Engl J
Med 293: 122-124, 1975.)
(By Permission)

As a result of this interaction, RNA synthesis is
increased and new proteins are synthesized.6 It
now seems that the appearance of progesterone receptors in breast tumors is the result of
estrogen stimulation and is a measure of hormonal responsiveness (Table 3). 1
The presence of estrogen receptor (ER) is
an important determinant of prognosis independent of the effects of age, nodal involvement and primary lesion size (Table 4).
The ER level is less in the tumors of younger
women and is less in primary as opposed to
metastatic tumor (Table 5).1
Estrogen receptor positivity successfully
predicts objective responses to hormonal therapy (Table 6) to the extent that only ER+ patients should be treated initially with ablation or
hormone administration. 1 ·8 It is of interest that
the perimenopausal patient, classically not responsive to hormonal therapy, tends to have
lower ER positivity than either the premenopausal or postmenopausal (five years or more)
patient. Clearly the traditional treatment decision based on premenopausal or postmenopausal status alone must be modified to
include ER status.

Estrogen-Receptor Negative/
Progesterone-Receptor
Negative
Estrogen-Receptor Positive/
Progesterone-Receptor
Positive

Ten-Year
Treatment
Failure Rate
Negative nodes
Positive nodes:
1-3
4 or more
All
All patients

Ten-Year
Survival

24%

65%

65%
86%
76%
50%

38%
13%
25%
46%

(Note: Adapted from the first NSABP Protocol)
(By Permission)

9/ 63

14%

67 / 91

74%

(Note: Adapted from McGuire WL: Hormone receptors:
Their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428-433 , 1978)
(By Permission)

Chemotherapy of Advanced Breast Cancer
A large number of chemotherapeutic
drugs have been shown to produce objective
responses defined as partial and complete responses (Table 7). Table 8 lists a number of the
commonly used agents and responses. The
early studies of Greenspan and others suggested that combination therapy was considerably more effective, and therefore the initial
chemotherapeutic treatment is almost always a
combination, most commonly Cytoxan-Methotrexate-5-fluorouracil (CMF). The CMF combination shown in Table 9 is based on an Eastern
Cooperative Oncology Group (ECOG) protocol
with 49 /93 patients responding . Complete responses lasted a median of eight or more
months, partial responses four to eight months.
Many oncologists, including myself, use less
Methotrexate, 30-40 mgm/M 2 , and one series
TABLE 4
Estrogen Receptor and the Prognosis for Early
Recurrence of Breast Cancer

Category

TABLE 2
Results of Surgical Treatment Alone

%
Response

Age:
Less than 50
Over 50
Nodes involved:

0
1-3
4 or more
Size of primary:
Less than 2 cm
Greater than 2 cm

Recurrence at 18 months(%)
EstrogenEstrogenReceptor
Receptor
Negative
Positive

34
35

14
8

12
38
62

6 .5
12.5
27.0

33
31

0
14

(Note: Adapted from Table 1, McGuire WL: Semin Oncol 5:
428, 1978, and Knight WA, et al: Cancer Res 37 : 4669,
1977 .) (By Permission)
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TABLE 5
Distribution of Estrogen Receptor in Primary and Metastatic Breast Cancer

Age:
ER level :
Under 3
3-10
11-1 00
101-2000

Primary Biopsy
Under50
50 or over
37%
20%
41%
2%

Metastatic Biopsy
50 or over
Under 50

23%
15%
36%
20%

52%
14%
29%
5%

31%
16%
27%
20%

(Note: Taken from Table 2, McGuire WL: Semin Oncol 5: 429, 1978.) (By Permission)

showed a 62% respon$e rate with CMF using
Methotrexate at 40 mgm/M 2 .
There is no doubt that the single most effective drug is doxorubicin hydrochloride (Adriamycin(R)) with reported response rates of up to
45%. Combinations using Adriamycin also show
a higher response rate than CMF or CMFP
(See Table 9), and some oncologists use CAF
as the initial treatment. It is, however, desirable to
have a combination available for use after the
initial treatment fails, and we have tended to
reserve Adriamycin for wse in relapse, usually
combining it with the vinca alkaloid, vincristine. 4
An exception to this sequence is the premenopausal, ER- patient with extensive visceral and bone disease. These women usually
have very rapid, progressive disease, and initial
treatment with CAF is warranted in an attempt
to obtain even a small measure of control of
their disease .
An additional consideration is the treat-

ment of the ER+ patient with. combined hormonal and chemical therapy. Only some 1020% of objective responses are complete responses, but patients achieving complete responses tend to have longer remissions and
better survival. Moreover, a small number may
be curable since the achievement of complete
response in large numbers of patients has been
associated historically with the development of
very long-term survival or cure. Thus attempts
to increase the number of patients achieving
complete response and to maintain those in
complete response for as long as possible are
now the subject of intense study.
Legha and his colleagues at the M. D. Anderson Hospital and Tumor Institute recently reported on 11 6 patients with breast cancer
achieving complete remission . A marked improvement in the number in complete response
and the duration of complete response was
seen in premenopausal patients who underwent

TABLE 6
Objective Response by Therapy and Estrogen .Receptor
Therapy

#%

Objective Response / Evaluable Patients
ER #%

40 / 76 (53%)
28/43 (65%)
9/14 (64%)
77 / 133(58%)

4 / 41 (10%)
2/74 ( 3%)
0/12 ( 0%)
6/ 127( 5%)

28%
29%
33%

10/28 (36%)
38 / 60 (63%)
15 / 32 (47%)
63 / 1 20(53%)

2/22
2/ 49
0/ 19
4 / 90

9%)
4%)
0%)
4%)

18%
36%
29%

12 / 17 (71%)
18 / 40 (45%)
30 / 57 (53%)

0/ 10 ( 0%)
0/ 15 ( 0%)
0/ 31 ( 0%)

ER+
Ablative Surgery:
Adrenalectomy
Oophorectomy
Hypophysectomy
Total
Hormonal Therapy:
Androgens
Estrogens
Glucocorticoid
Total
Antiestrogens:
Nafoxidine
Tamoxifen
Total

(
(
(
(

Pre-ER patients
(All comers)

33%

(Note : Adapted from Table 2, Legha SS et al: Ann Intern Med 88: 69, 1978, and Table 4 , Carbone PP , Davis TE: Semin Oneal
5: 417, 1978.) (By Permission)
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TABLE 7
Tumor Response
Complete Remission

Complete Response
Partial Response

Stable Disease

Progressive Disease

No clinical evidence of active
tumor; no subjective evidence
of disease
All measurable disease disappears
50% or greater reduction in measurable tumor in the absence of
progression or recurrence of
new lesions elsewhere
Steady state or response less than
50% reduction in measurable
tumor. No increase in size of
any lesion or appearance of
new lesions
Occurrence of any new lesion or
increase of any measurable
lesion> 50%, even in the face
of regressing lesions
elsewhere

(Note. Adapted from Carter SK: The design of clinical trials

in cancer therapy (ed. M Staquet) Brussels: Editions Scientifiques Europeennes, 1972.) (By Permission)

oophorectomy and received chemotherapy immediately compared to women receiving chemotherapy when disease progression occurred.9
An earlier study of adrenalectomy, oophorectomy and chemotherapy by Hoge et al revealed a much higher objective response rate
(80%) when compared to chemotherapy or hormonal ablation alone. 10 These and other studies
suggest that attempts to increase the number of
patients in complete response by combined
therapy may be worthwhile. However, such
studies remain research protocols, and much
longer observation will be necessary to assess
their true value.

Adjuvant Chemotherapy
The large number of patients failing to
achieve cure following radical mastectomy sug-

TABLE 8
Summary of Single Agents Active Against Advanced Breast Cancer

Drug
Alkylating agents:
Cyclophosphamide
Nitrogen mustard
Phenylalanine mustard
Chlorambucil
Thio-TEPA
Antimetabolites:
5-Fluorouracil
Methotrexate
6-Mercaptopurine
Arabinosyl cytosine
Vinca Alkaloids:
Vincristine
Vinblastine
Antibiotics:
Actinomycin D
Adriamycin
Bleomycin
Mithramycin
Mitomycin
Miscellaneous agents:
Hydroxyurea
BCNU
CCNU
Methyl CCNU
Hexamethylmelamine
lmidazole carboxamide
Procarbazine

No. Evaluable
Patients

No. Objective
Responses

Response
(%)

529
92
86
54
162

182
32
20
11
48

34
35
23
20
30

1263
356
45
64

324
120
6
6

26
34
13
9

226
95

47
19

21
20

44
193
8
32
60

5
67
0
5
23

11
35
0
16
38

21
76
155
33
39
29
21

4
16
18
2
11
2

19
21
12
6
28
7
5

(Note: Compiled by Susan J. Mellette, MD , Professor of Medicine, Medical College of Virginia.)
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TABLE 9
Useful Drug Combinations In the Treatment of Breast Cancer
Regimen
CMFVP

CMF

CMFP

AV

CA

CAF

DAV

Drug Dosage

Response Rate(%)

and Schedule

Cyclophosphamide 80 mg / m 2 p.o. daily
Methotrexate
20 mg / m 2 i.v . weekly
Fluorouracil
500 mg / m 2 i.v. weekly
Vincristine
1 .0 mg / m 2 p.o. daily x 15
Cyclophosphamide 100 mg / m 2 p.o. days 1- 14
60 mg / m 2 i. v. days 1 & 8
Methotrexate
5-Fluorouracil
600 mg / m 2 i.v. days 1 & 8
(repeat cycles every 4 weeks)
Cyclophosphamide 1 00 mg / m 2 p.o . days 1- 14
60 mg / m 2 i. v. days 1 & 8
Methotrexate
5-Fluorouracil
600 mg / m 2 i.v. days 1 & 8
Prednisone
40 mg / m 2 p.o. days 1-14
(repeat cycles every 4 weeks)
Adriamycin
75 mg / m 2 i.v. day 1
Vincristine
1 .4 mg / m 2 i.v. day 1 & 8
(repeat cycles every 3 weeks)
Cyclophosphamide 200 mg / m 2 p.o. days 3-6
Adriamycin
40 mg / m 2 i.v. day 1
(repeat cycles every 3-4 weeks)
Cyclophosphamide 100 mg / m 2 p.o . days 1-14
Adriamycin
30 mg / m 2 i.v . days 1 & 8
500 mg / m 2 i.v. days 1 & 8
Fluorouracil
(repeat cycles every 4 weeks)
Dibromodulcitol
150 mg / m 2 p.o . days 1-10
Adriamycin
45 mg / m 2 i.v . day 1
Vincristine
1 .2 mg / m 2 i.v . day 1
(repeat cycles every 4 weeks)

(Note: From Table 3 . Carbone PP , Davis TE : Semin Onco/ 5 :417 , 1978.)

gests that breast cancer is in fact a systemic
disease at a very early stage , if not at its onset .
There is increasing evidence to support a multicentric origin for many tumors including breast
cancer, and it is now apparent that very large
numbers of cells are shed systemically by even
small cancers . Moreover, surgical failure results
in local recurrence in only about 15% of cases,
and most of these patients eventually show dissemination at other sites. 4 Adjuvant chemotherapy given after surgery is designed to destroy
disseminated tumor cells and increase the likelihood of cure.
Two major groups have studies in progress: the National Surgical Adjuvant Breast Project (NSABP) and the National Tumor Institute in
Milan. 11 · 1 2 • 13 The initial NSABP trial used a
single drug , L-phenylalanine mustard, and the
first Milan study used CMF for 1 2 cycles . Benefit was seen in premenopausal patients with one
to three nodes involved in both series and for
four or more nodes in the Milan series. Tables
1 OA and 1 OB show data updated to four years

1 02 /
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(then taper) !
53

63

52

74

82

71

(By Permission)

as of May 1 9 7 8 and represent the most recent
comparative data. No benefit to premenopausal
women without nodal involvement has been
demonstrated . The situation for postmenopausal women is less certain at present
because the Milan study is reported to show
benefit for the woman with four or more nodes
who is able to take 85% or more of the scheduled adjuvant chemotherapy. 13 The NSABP
data do not show benefit. Therefore adjuvant
therapy should be reserved for premenopausal
women with one or more positive axillary nodes.
To date, a clear-cut advantage for three drugs
and for the duration of treatment has not been
established, although treatment for six months
and 1 2 months does not appear much different
at the present. 1 4
Antiestrogens
A number of steroidal and non-steroidal
compounds have antiestrogenic effects. Most
clinical trials have employed the nonsteroidal
compounds nafoxidine and tamoxifen . The lat-

TABLE 10
A. Comparison of NSABP /Milan Data
-Control Patients-

B. Comparison of NSABP /Miian Data
-Treated Patients-

% Disease Free

% Disease Free

at Four Years

at Four Years
Age /
Menopause
All Pts.
All Pts.
All Pts
49 / Pre50/ Post49 / Pre49 / Pre50/Post50 / Post-

Positive
Nodes

NSABP

Milan

All
1-3
4
All
All
1-3
4
1-3
4

51
63
40
43
56
54
35
67
43

47
54
32
41
52
49
23
58
42

Age/
Menopause
All Pts.
All Pts.
All Pts.
49 / Pre50 / Post49 / Pre49/Pre50 / Post50 / Post-

Positive
Nodes

NSABP

Milan

All
1-3
4
All
All
1-3
4
1-3
4

59
74
40
65
56
86
40
68
40

66
74
49
75
56
87
51
61
1 45
5 / 78

5/ 78

-

(Note: Courtesy of Dr. Bernard Fisher and the National Surgical Adjuvant Breast Project.)

ter is commercially available and is believed to
bind to the estrogen receptor in the cytosol,
translocate to the nucleus, and bind to chromatin but not release easily. Cytoplasmic receptors
also are depleted after tamoxifen therapy. It is
clear that the effectiveness of antiestrogenic
treatment correlates very well with estrogen-receptor positivity. An overall response rate of
about 33% is seen, but the rate in ER+, postmenopausal patients is as high as 60%. 15 This
is similar to the percentage of tamoxifen response in patients previously responding to hormonal therapy. Patients failing to respond to
hormonal therapy usually do not respond to tamoxifen.
Most studies have been done in postmenopausal patients, but benefit in premenopausal patients has not been excluded .
The dose is 1 0 mgm by mouth twice a day and
is usually tolerated well . Nausea and vomiting
are seen in some patients (12% in one series),
hot flushes in about 21 %, hypercalcemia occasionally , and mild platelet count depression
rarely.
Synthesis
The management of the patient with
breast cancer increasingly depends on careful
staging taking into account the major prognostic features outlined above. The patient _with localized disease, small primary and no axillary
nodes is probably best served at present by
modified radical mastectomy or radical mastectomy, although studies in progress at a large
number of centers are beginning to suggest that

less extensive surgery with radiation therapy to
the chest wall and nodes may be useful in selected cases. Knowledge of the presence or absence of axillary node metastasis and the number of nodes involved is of such central
importance to prognosis that procedures which
do not provide this information cannot be considered useful at this time .
Premenopausal patients with one or more
positive nodes but without evidence of metastatic disease elsewhere should be considered
candidates for adjuvant therapy. However, the
question of whether adjuvant cytotoxic chemotherapy, immunotherapy, or hormonal therapy
should be given and for how long remains in the
investigative stage. Adjuvant chemotherapy
with CMF cannot be considered of proven value
for the general population of patients, and every
effort should be made to include these patients
in clinical trials to establish the value of adjuvant
therapy.
The choice of therapy for the patient with
extensive disease also has become more complex. ER+ patients of advanced age with cutaneous, pleural , nodal, early bone, or nodular
pulmonary disease may respond well to estrogen administration, and on re-exacerbation,
androgen or prednisone. Approximately 25% of
these patients will show regression of the tumor
when estrogen is stopped-the "rebound"
phenomenon, which has also been described
after androgen and tamoxifen therapy.
The premenopausal, ER+ patient currently is treated with oophorectomy initially and,
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TABLE 11
Metastatic Disease
Postmenopausal

Premenopausal
ER+

ER-

ER-

Oophorectomy
Medical adrenalectomy
Surgical adrenalectomy
Antiestrogen
Chemotherapy

Chemotherapy

upon relapse, adrenalectomy or hypophysectomy . In a series studied at the Medical College
\ of Virginia, 16 medical adrenalectomy with amino. glutethimide and dexamethasone is almost as
effective as surgical adrenalectomy and does
not preclude a response to surgical adrenalectomy when tumor again progresses. A schematic flow sheet to indicate serial treatment
measures for advanced disease is shown in
Table 11.
The presence of extensive long bone metastases or vertebral destruction should be handled with radiotherapy to as small an area as
possible. Some cases may require prophylatic
internal fixation of the femur or humerus.
Prompt laminectomy and decompression of the
spinal cord in epidural tumors or vertebral collapse is always worthwhile. Chemotherapy
rather than hormonal therapy will almost always
be required in such cases because of ttie need
for rapid control of the disease to ensure continued ambulation.
CNS involvement can frequently be handled with moderate doses of radiation to the
whole brain (3000 rads in 1 0 fractions), but
meningeal involvement may also require intrathecal Methotrexate administration.
Liver metastases, extensive visceral in-

ER+
Estrogen
Estrogen rebound
Androgen
Androgen rebound
Antiestrogen
Progesterone or Corticosteroid
Chemotherapy

volvement, bone marrow, or interstitial pulmonary involvement present almost insurmountable management problems. However,
some patients with liver metastases and marked
liver dysfunction respond to cytotoxic drugs and
these should be instituted . When the situation is
desperate, doxorubicin containing regimens
with their higher initial response rate are the current choice. Extensive involvement of more than
one organ requires cytotoxic drugs for systemic
effect and radiation of painful or obstructing
masses of tumor.
Corticosteroids provide some short-term
palliation of the patient with interstitial pulmonary involvement. When bone marrow involvement with persistent low blood counts precludes full doses of multiple drugs administered
on the usual time schedules, reduction of doses
and/or the number of drugs may still provide
some means of control .
Some general tenets of management of
the patient with breast cancer are summarized
in Table 12 . In all cases the most critical aspect
of management is the close support of the patient by an understanding and sympathetic physician.

REFERENCE$
TABLE 12
Tenets of Breast Cancer Management
1 . Make long-term plans for the management of the patient
at the onset.
2. Preserve or restore mobility and CNS function.
3. Treatment of painful lesions is virtually always of benefit.
4. Start treatment for local recurrences or systemic disease
early; do not delay.
5. Neither despair nor hold out unrealistic promise of cure.
Hope is warranted by the facts .
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Tapping the Tube
SARA KAL TREIDER , MD

The Old Way$
Before percussion and mediate auscultation were discovered, methods of physical examination-in particular chest examinationwere limited . Only observation was used with
any regularity. From the time of Hippocrates,
palpation and direct auscultation had been used
sporadically to detect heartbeats but had not
proved to be of practical value because clinicopathological correlation had not yet been established. At last, when a new method called
percussion was conceived by Auenbrugger in
1 761, it was ignored for almost forty years . Not
until the French School evolved did percussion
become established, largely through Corvisart,
Napoleon's private physician . Coincident with
the revival of percussion, Laennec, another
physician of the French School, invented the
stethoscope and mediate auscultation . How remarkable that these two methods of chest examination came into use at the same time and
in a period of history when chest disease--especially tuberculosis-was rampant!
Until the mid-seventeenth century systematic instruction in clinical examination was nonexistent; no patient contact was required for
medical training or degrees, and it was necessary to pass only an oral test. Two great clinicians, Sydenham and Boerhaave, who practiced in the seventeenth century, helped to
change this pattern and emphasized the importance of observation as a method of clinical examination.
Thomas Sydenham (1 624-1 689), an
Englishman , had barely begun his college career when it was interrupted by the Civil War.

[I should like to acknowledge the help, encouragement and inspiration given to me by Dr G. J. Cunningham
and Dr F. J. Spencer.]
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Four years later when the war between the King
and Parliament was over, Sydenham felt too old
to start a college education again . "At a loss for
a career ," he decided to study medicine at Oxford. 1 Because of his war experiences and his
brief formal medical education, Sydenham's
approach to medicine was practical and relatively unspoiled by the old theorizing which was
popular until his time . Sydenham realized the
need for practical clinical study as he expressed
in his words: '' .. . the human mind is far too
limited in its ability and knowledge to settle the
great problems of what disease is, and why
there should be disease. While we debate such
questions there are sick men who need help.
.. . The place to study disease is at the bedside
of the sick man : by observation and experience
we can learn the nature of disease. " 2 He recorded thorough observations on many diseases including scarlet fever, measles, chorea,
smallpox , malaria, and dysentery, but his masterpiece was a meticulous description of gout, a
disease from which he himself suffered . Because his style of clinical observation and description resembles that of Hippocrates, Sydenh am has earned the title the ''English
Hippocrates.' ' 3
Hermann Boerhaave (1668-1 738) also
stressed clinical observation and popularized
bedside medicine. He was born in Holland, the
son of a clergyman, began his studies in theology at Leyden , and, becoming interested in the
sciences and medicine , he resolved to become
a doctor. Respected and loved by his pupils as
a physician, he was able to promote new ideas
on the nature of disease. "A disease," he said,
"is a physical thing and its cause is also a physical thing . . . which induces a change in the
solids and fluids of the body. " 4 Boerhaave was
a pioneer in associating clinical features of disease with post-mortem appearances, although

clinicopathological correlation did not reach its
ful l potential until later through the work of Morgagni.
During Boerhaave's time, and still later in
the eighteenth century, examination of a patient's unclothed body remained a rarity even in
the case of infants. Boerhaave, however, after a
history had produced no clues, would resort to
physical examination. An account is given of an
infant taken to Boerhaave with a fever of unknown origin. After an unrevealing history, he
demanded that the infant be undressed ,
whereby he discovered a needle in its body as
the source of infection .5 Besides observation ,
Boerhaave instituted other tools in his practice
at Leyden; he used the Fahrenheit thermometer, looked at blood and urine under the microscope, and routinely performed autopsies.6
These methods and ideas were propagated and
spread throughout Europe, and his fame extended even to China. His students came from
several foreign countries, and his influence on
other universities was considerable. Two of his
pupils, Van Swieten and de Haen, were responsible for the development of the old Vienna
School, and all the founders of the Medical
School at Edinburgh trained under Boerhaave.
Bedside observation and post-mortem examination became important traditions in these
schools, and it was in Vienna that Auenbrugger
studied and made his remarkable discovery.7
Percussion
Leopold Auenbrugger (1 722-1809), born
at Gratz in the Austrian province of Styria, was
the son of an innkeeper and often helped his father in the inn. He completed his medical studies under Van Swieten at the Vienna School and
became an attending physician at the Spanish
Military Hospital of the Holy Trinity (1751 ). This
large hospital, the finest in Vienna, provided
abundant opportunities for clinical observations,
and over a seven-year period, Auenbrugger
tested his famous discovery.8 The idea of percussion came about as Auenbrugger was tapping on wine barrels in his father 's inn to locate
the fluid level without having to open the barrels. In this manner he could determine when
the supply was dwindling, the hollow sound indicating emptiness. He ingeniously applied the
new principle of percussion to his patients and
fo und that he could detect consolidation ,
pleural effusion, and even cardiac dilatation.

Not only did he confirm his diagnostic impressions at autopsy, but he also tested his method
by injecting fluid into the pleural space in cadavers and then percussing them to find the fluid
level .9
Auenbrugger published his findings in
1 7 61 in " lnventum Novem, " a modest 9 5page volume which has become a medical classic . The full translated title of the book is A New
Discovery that Enables the Physician , From the
Percussion of the Human Thorax , to Detect the
Diseases Hidden Within the Chest. 1 0 Auenbrug-

ger ' s observations are found in Camac 's
Epoch-making Contributions to Medicine11 and
are now summarized . First, a description of the
normal chest sound and its characteristics in
different areas is presented . In the healthy state
this sound is like a " stifled drum covered with a
thick woolen cloth .' ' Variation according to
body habitus is explained, the sound being
more prominent in the lean and almost lost in
the obese. The technique for percussion is suggested: the chest is "struck slowly and gently,
with the points of the fingers brought close together and at the same time extended ." Methods are given for percussing the clothed and
unclothed chest, positioning the patient, and instructing him how to breathe. Next, the dull
sound called the "preternatural " or "morbid "
sound is described. In this part an analogy is
drawn between a cask of fluid and a chest with
effusion . Other observations relate those diseases producing the dull sound ; for example,
inflammation of the pleura or lungs, serous ,
purulent, and bloody effusions, pericardia! effusion, cardiac enlargement; and those diseases
not causing a dull sound ; for example, asthma,
consumption , small lesions.
Interestingly, Auenbrugger, with much insight and wisdom , had stated in the preface of
his book , " I realize ... that envy and blame
. and even hatred and calumny have never failed
to come to men who have illuminated art or sci. ence by discoveries. " 1 2 Indeed , his master~
piece did not immediately achieve the attention
and success it deserved. Van Swieten , to whom
Auenbrugger almost dedicated his book, failed
to comprehend the value of percussion. De
Haen , who lamented the " obscurity and difficulty of diagnosis of thoracic disease,' ' likewise
never acknowledged percussion and its possibilities. 13 Others either ignored or grossly misinterpreted the "lnventum Novem " as did
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Rudolph Vogel, an authority in medicine in Gottingen, who mistakenly wrote that Auenbrug- ·
ger's percussioh was only a variat.ion of Hippocrates' succussion , and was annoyed that
Auenbrugger did not give credit to Hippocrates. 14 The succussion splash known to Hippocrates was a sign pathognomonic of seropheumothorax and heard less often with
pyopneumothorax; it really depended on the
presence of both air and fluid in the pleural cavity. Hippocrates elicited this sign by shaking the
patient 's shoulders and either listening from
arm's length or with the ear to the chest when
he would hear a "splash" or metallic tone .
Despite the lack of enthusiasm for his discovery, Auenbrugger lived a happy life. He was
well accepted among his peers for his congeniality and loved by his students for his generosity and compassion. He enjoyed a golden anniversary with his wife, a peaceful retirement in
the suburbs, and died at the age of eightyseven . His method was only temporarily put to
rest and was later revived by the French physician, Corvisart. Still later, after percussion had
gained popularity, another French physician
named Piorry promoted a modified form of
Auenbrugger's method, mediate percussion ,
which is still used by modern physicians.

The French School and the New Medicine
In the last few years of the eighteenth century, France was experiencing a Revolution in
medicine as well as in politics. The philosophical mood which favored observation, experience, and skeptical empiricism instead of the
classical beliefs, carried over into the field of
medicine and the famous French School in
Paris.
All remnants of the old regime were swept
aside by the Revolution, and the universities
and medical colleges closed. A few years later
when France was at war, the shortage of doctors became serious, and the only places available for training were the hospitals. The hospitals became "the workshops of new medicine,"
and according to the historian Ackerknecht,
'' .. . it was only in the hospital that the three pillars of the new medicine-physical examination , autopsy, and statistics could be developed . " 15
The hospital clinical training as formulated
during this period sounds surprisingly similar to
today's attending round . "The professor would
108 /
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pause at the bedside of each patient long
enough to question him and examine him properly; he would draw the students' attention to
the diagnostic signs and the important symptoms of the disease . . . . '' 16 The students
would "read little, see much, and do much ,"
learning as they practiced at the bedside. 17
Thus the French School gave birth to medicine
as it is practiced today, produced many great
physicians, and became the leadihg school in
Europe.

The Revival of Percussion
Jean Nicolas Corvisart (1755-1821) was
an eminent figure in the French School, and as
a proponent of percussion and teacher of Laehnec, he became ''the connecting link between
the men who did the most for the practical science of medicine' '-Auehbrugger and Laennec .18 Corvisart began His career in surgery and
anatomy but then turned to internal medicine. In
1782 he was rejected for a position at the
Necker Hospital despite excellent qualifications
because he ref used to wear a powdered wig!
However, he successfully held positions in subsequent years at the Charite, Ecole de Sante,
and College de France.
It was in 1 799 that Corvisart came upon
Auenbrugger 's work through a book by Eyerel ,
a student of the Vienna School who praised the
method of percussion . Giving full credit to
Auenbrugger, Corvisart found and translated
the original "lnventum Novum" from Latin into
French, added to it his own commentaries, and
published the entire work in 1808. Two years
previously, Corvisart had published a book oh
heart disease, Maladies du Coeur, in which he
brilliantly discussed pericarditis, cardiac dilata.:.
ti on and hypertrophy, cardiomyopathy, and valvular and aortic disease. However, by far his
greatest gift to modern medicine was the revival
and propagation of percussion, so that by 1825
it was in use practically everywhere. 19
In 1804, Corvisart was selected to be Napoleon's physician, in part because of the Emperor's appreciation of percussion. Corvisart
was called into consultation for a persistent cold
bothering Napoleon, who was impressed when
this great physician used percussion in his examination. 20 In 1815 , following the downfall of
Napoleon, Corvisart retired from medicine altogether and in 1821 died of a stroke. One of his
most outstanding qualities was his ability to in-

spire and encourage his pupils and their ideas.
He closely assisted his students, particularly in
bedside observation. In this way, Laennec
came to know and esteem Corvisart and to become his favorite pupil.

Mediate Auscultation
Rene Theophile Hyacinthe Laennec
(1781-1826) was born at Ouimper in Bretagne, a province in northern France. His
mother, having exposed Laennec to tuberculosis, died of the disease when he was six years
of age. Consumption shortened Laennec 's life
as well but did not hamper his productivity. His
father, who was an eloquent lawyer but irresponsible and always in debt, sent his sons to
live with their rector grand-uncle at Elliant. At
age 11 Laennec went to Nantes to live with his
uncle Guillaum Laennec, a physician and faculty member at the University of Nantes who
was instrumental in Laennec's decision to study
medicine.
Laennec's early education was interrupted by the French Revolution , but at age 19,
after much deliberation, he went to the renowned Paris School to study medicine. In the
year that followed, he won two prizes given in
medicine and surgery at the University of Paris.
At age 23 he successfully completed a medical
thesis on Hippocrates. Following his formal
medical training, he spent four years as physician at Beaujon Hospital in Paris and then obtained a position at the Necker Hospital where
he made his famous discovery of mediate auscultation .
The examination of the chest just before
Laennec's discovery consisted of inspection,
palpation, the newly added method of percussion, and immediate or direct auscultation.
Auscultation in this form was known to Hippocrates but was neither popular nor frequently
used. It had a number of disadvantages. Some
patients, if not most, were unwashed or vermininfested, making direct contact undesirable.
Other patients had a voluminous amount of fat
which rendered the method somewhat less useful; furthermore, direct auscultation proved to
be an embarrassment to the female patient.
As immediate auscultation ''shocked his
decency and modesty," Laennec himself used
it only in cases of suspected heart disease when
the heart beats could not be felt by palpation. 2 1
In his own words, ''(It was) as uncomfortable for

the doctor as it was for the patient, disgust in itself making it impracticable in hospitals. It was
hardly suitable where most women were concerned and, with some the very size of their
breasts was a physical obstacle to the employment of this method .... " 22

The Tube
In 1816, Laennec was consulted at the
Necker Hospital by a young female patient
thought to have heart disease. On his way to
visit this patient, he saw several children playing
on some lumber in the gardens of the Louvre,
and he was reminded of an acoustic principle.
As one child tapped on the beam at one end,
the signal reached the other child with his ear
on the opposite end . Excitedly, Laennec hurried
to the bedside of his patient with a cylinder of
tightly rolled paper tied with string and found
that by placing this instrument between his ear
and the patient, he could hear heart sounds
more clearly than ever before. It immediately
occurred to him how useful this method might
be in studying all movements produced in the
thora x-breath sounds, voice , wheezing,
pleural and pericardia! effusions. 23
Laennec called the new method '' mediate
auscultation ," " auscultation" for the method in
its direct form begun by Hippocrates, and "mediate' ' for the interposed instrument. The term
" auscultate" originated from the Latin "ausis,"
to hear, and " culto," to cultivate, and meant to
give attention through hearing. 24 Laennec
named his tool the "stethoscope" combining
"stethos" meaning chest and " scope" from
the Greek word meaning to examine. Other
names initially applied to the invention included
"a pectoriloquy," " medical trumpet," "the cylinder," or " the tube. " 25
Laennec and everyone else at the Necker
Hospital began experimenting enthusiastically
with the tube. He varied the length, width, and
central hollow, and decided upon a one-foot
cylinder with a quarter inch central space which
he accidentally found to be necessary for listening to the voice . A solid cylinder, he discovered ,
would suffice for heart sounds, breath sounds,
and rhonchi ; however, breath sounds and
rhonchi were augmented with the central hollow
plus a cupped shape carved at the end . Many
materials were tried-"ebony, cedar, malacca
cane, lime wood, glass, various metals, . . .
gold-beater's skin .. . . '' 26 He even used his
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cousin's oboe but finally decided a light beechwood was his preference.27
Early in 1 81 8 Laennec , having collected
his preliminary observations, demonstrated his
new method and instrument to the Societe
d'Ecole. Though he thought it was premature to
publish his findings , he felt he should speak for
his work as others were mentioning his invention in various publications. At this time he had
recorded an outline for his book and was experienced in separating normal from abnormal
chest sounds. In the same year he presented
his findings to the Academie Medecine, which
appointed a commission for study of the
method. Laennec continued to accumulate data
and propose new applications for the stethoscope . A key case was that of Madame de
CMteaubriand who had recurrent hemoptysis
and had been diagnosed by a previous consulting physician as a consumptive in the terminal
stage. Laennec , finding no signs of cavitation
by stethoscope , confidently diagnosed bronchiectasis ; CMteaubriand lived to age 75 .28
This differential diagnosis was encountered now
and then and was important to the patient as it
made the difference between a life or death
prognosis.
In attempting to expand his method 's appl ication, Laennec reportedly suggested a
means of helping deaf-mutes.29 He also , on occasion , extended his professional career to include auscultating animals. During his countryside vacations which he took only to convalesce
from exacerbations of tuberculosis , he was
seen auscultating his dogs, " Kiss" and " Moustache .''
In April 1819, he delivered to the publisher the final product of his labors, De
/'auscultation mediate, OU Traite de Diagnostic
des maladies des poumon et du coeur fonde
principalement sur ce nouveau moyen
d 'exploration ; also known by the shorter title,
Traite de /'Auscultation Mediate.30 To provide
the editor with an ample supply of stethoscopes
to sell with his book , Laennec spent countless
hours at his lathe meticulously making the
wooden instruments. The book was ready for
sale in August 1 81 9 for 13 francs ; and the
stethoscopes sold for three francs each .3 1 A further edition of his book followed in 1826.
Laennec's stethoscope flourished in many
countries: England , where consumption was
raging , Germany, Italy, Spain, Holland, Swe11 0 / KAL TREIDER : TAPPING THE TUBE

den , Russia , Poland and even across the Atlantic in America. About 35 years after its discovery , a binaural model was designed by George
Philip Camman of New York . Other varieties refining the original were developed from time to
time including the modern diaphragm type.

Laennec's New Signs
Laennec described most of the stethoscopic signs used in modern medicine; not only
did he describe them , but as an experienced
pathologist he was able to correlate them with
autopsy findings, distinguishing numerous conditions including tuberculosis or pulmonary
phthisis as it was called then , bronchitis , bronchiectasis , emphysema , asthma, pneumonia ,
and pleurisy . Here are some of the signs Laennec left to medicine :
= goat +
phone = sound , sound similar to the bleating of a goat; heard at the upper border of an
effusion .
Amphoric resonance. Latin amphora = a jar,
also has Greek derivation , sound resembling
that heard when blowing into an open bottle ;
indicates cavity.
Bronchial respiration . Greek bronchos = windpipe , Latin similar, sound heard over larynx,
trachea , large bronchi; increased in pneumonia and dilatation of bronchi.
Cavernous respiration . Latin caverna = a cavern , similar to amphoric breathing , hollow
sound ; indicates cavity.
Crepitant rcj/es. Latin crepitus = little noises,
crackling ; pulmonary edema.
Metallic tinkling. Sound as made by sand falling
into metal cup; indicates cavity.
Pectoriloquy. Latin pectus = breast + loqui =
to speak , voice sounding very close to ear
through stethoscope ; sign of cavity.
Pleural friction . sound resembling rough surfaces rubbing together; heard in tuberculous
pleuritis.
Puerile breathing. Latin puer = boy , respiration
heard in child , sonorous with marked inspiration .
R~les. French r~ler = to rattle , crackling
sounds; Laennec described them as moist or
crepitant, mucous or gurgling , dry or sonorous (snoring) , dry sibilant (whistling) ;
heard in multiple situations depending on
character.

Aegophony. Greek ai x or aegis

Rhonchus. Greek word-snoring, Latin

rhonchus = snoring , sound heard in many
conditions-pneumonia, tuberculosis, bronchitis ....
Vesicular respiration. Latin vesicula = little
bladder, breath sounds heard over normal
lung fields except over trachea and mainstem bronchi. 3 2

The Test of Time
Most of the signs Laennec discovered
with his stethoscope have remained important
to the modern physician. Some are more frequently used than others; for instance, vesicular
and bronchial breath sounds, r~les, rhonchi,
pleural friction rub, and aegophony. Those
signs associated with cavitary disease, however, are less often encountered because of the
decline in advanced pulmonary tuberculosis,
specifically amphoric or cavernous breathing
and pectoriloquy. Two terms have wider clinical
application than realized by _Laennec: aegophony, heard above pleural effusions, is sometimes found in consolidation; pectoriloquy can
be used to detect early pneumonia, atelectasis,
and infarction .
Yet another method of chest diagnosis
has come to be used since Laennec-the Xray. With the X-ray the physician has been able
to look into the chest and actually see pathologic changes. It enables him to confirm with his
eyes what he has heard with his ears and also
to detect lesions not producing stethoscopic
findings. Even so, the stethoscope remains the
most convenient and the quickest method of
forming diagnostic impressions, determining the
need for further diagnostic work-up, and clinically following disease processes in the chest.
Laennec's auscultation has survived the
test of time, and along with Auenbrugger's percussion has become a permanent part of systematic chest examination. The chest and its
diseases which for so long were mysteries to
the clinician began to be solved with these
methods . After Laennec, vast numbers of
books on chest disease appeared. Though
Laennec did more to elucidate pulmonary than
cardiac disease, his invention cleared the way
for Corrigan and Stokes of the Irish School to
make further advances in the realm of cardiac
and pulmonary diseases. Thus, the coincident
establishment of percussion and auscultation by
the French School has certainly been among

the greatest milestones in physical diagnosis,
adding two new methods to chest examination
and offering new frontiers for the clinicians who
followed.
As a final note, new uses may be found
for auscultation. A recent author described a
new variation combined with carotid phonoangiography. It consists of auscultating bruits
with a special microphone connected to an oscilloscope. 33 These bruits are recorded graphically and evaluated in terms of percentage stenosis. This is one non-invasive means of
determining which patients with transient ischemic attacks would benefit from caroted arteriography. Thus, auscultation, used in its traditional form with the binaural stethoscope, has
developed new applications which may expand
further in the future.
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Colonial Cultivation and Concoctions
SARA JONES GOMBERG, MD
Have you ever wondered how to increase
the value of your property? One way would be
to include a well-cultivated herb garden ; that is
if you were a seventeenth-century colonist. Not
only were the herbs much sought after for their
culinary uses but also for their medicinal properties. Today 's medical library may not include a
collection of botany books, yet botanical knowledge was a large part of early medical tr(lining
and the mainstay of the " cavalier concoctions "
used by colonists for medical treatment .
In gathering together its first 225 settlers
to go to America, the directors of the Virginia
Company of England instilled a sense of responsibility in these adventurers to discover
plants for medicinals. A few colonists were lured
by the prospects of a profitable drug trade. After
all, the Spaniar_ds were doing well and had a
monopoly on the drugs and spices from South
America, in addition to the gold. They were
even attempting to block the transplanting of
the New World plants. Besides profits, the Virginia Company did have some concern for the
health and welfare of these first settlers, and of
the first 225, seven were medical professionals.
The medical profession in England had, at
that time , emerged as three distinct groups: the
apothecaries, physicians, and barber surgeons.
The development of these three groups is a
topic unto itself. Briefly, the word " apothecary "
goes back to Norman times, meaning anyone
who kept a shop of such non-perishable commodities as spices, drugs, comfits, and preserves. At the time of the " Jamestowne expedition ,'' the apothecaries were incorporated with
the Grocers Guild , hence the apothecary's interest in spices and such. In 1 61 7 , James I
granted the apothecaries a separate charter. At
various times throughout the seventeenth century , the apothecary emerged as not only the
dispenser of medicine but also as the general
practitioner of medicine.
The physicians were the elite of the original groups. They did not want to concern them~

selves with " general practice," yet they did not
want the apothecaries to sell medicine without a
prescription from a physician . The physician ; in
a classical sense, was the best educated and
had behind him the tradition of the Royal College, which had been founded in 1518.
The barber surgeons had been organized
since 1540 and were the least educated of the
three. They assumed responsibility for any " mechanical " treatment needed by their clients.
From the three groups ; at times rivaling one another, the Virginia Company attracted seveh
members. These were apothecaries Thomas
Field and John Harford, the physician Walter
Russel , and four barber surge0ns: Will Wilkinson, Thomas Wotton, Post Ginnat, and Tho
Cowper. Only one of the barber surgeons was
included among the 1 44 passengers who first
came to Virginia in 1607, and the remainder of
the professionals were members of the second
sailing in January 1 608 .
Times were rigorous for these early colonists, and their famines, unfamiliar fevers, and
flixes took their toll. By January 1 608 , when the
first supply ship arrived, only 38 of the original
settlers were still alive. The surgeon who accompanied the first expedition is not mentioned
after 1607 in any extant records . The two
apothecaries and one physician mentioned before were not noted in the records, and it is presumed that they, like the majority of the new inhabitants , did not survive. Because these
settlers had to treat their ills as best they could
with little medical guidance and few materials,
there was the impetus for them to discover native plant remedies.
The colonists made requests to the Virginia Company to send them medical supplies
and personnel , but communications being what
they were, they did not receive their next physician, Dr Lawrence Bahun , until 1610 . Trained
in Leyden, Bahun was a well-educated man
who stayed for only one year in Virginia before
returning to England . It is uncertain how much
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he added to the well-being of the colony as he
spent most of his time investigating the medicinal properties of the local plants . He experimented with a white clay that he claimed had
absorbent and "aiexipharmic " properties. His
vegetable remedies included the abundant sassasfras and Galbanum mechoacon or rubarbum
alum . Rubarbum alum was thought to be good
for the " purginge of fleame and superfluous
matter.''
Bohun returned to England with Lord
Delaware , leaving the colonists without any
medical authority for the period from 1 611 to
1 621 . Again , they complained of their plight to
the Virginia Company . Dr Bohun was appointed
Physician-General in 1 620 but was killed en
route when Spaniards attacked the ship on
which he was traveling. In 1621, John Potts
was selected to replace him . He was accompanied by anapothecary , Joseph Fitch , and on
his arrival took on one of the colonists , Mr
Townsend , as an apprentice . But once more disaster intervened as Joseph Fitch was killed in
the Indian Massacre of 1622. There is no record of Mr Townsend 's practicing as an apothecary , and indeed , of no practicing apothecary .
until the eighteenth century . This is probably related to the collapse of the Virginia Company in
1624 , after which there would have been a lack
of organized travel facilities for prospective emigrants and no promises of profit which might
have attracted medical professionals.
The colonists were , therefore , left to take
medical care into their own hands both for
themselves and their families . Anyone who
showed skill in the treatment of disease or ability in the use of local plant remedies quickly became recognized. The local Virginia legislature
responded by passing a law in 1632 that required the parish minister to assist the sick . Occasionally a supply ship 's surgeon , while in
port , would care for the sick colonists or might
even settle in the colony himself. If he did , he
was generally considered a ship 's surgeon
" that knows nothing above the common remedies-not acquainted with plants or the other
parts of the Natural History to be any service to
the worlde .' '
As the p!antation system developed , it became necessary for the owners to become well
versed ih the local remedies to preserve the
health of their family and servants. A number of
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publications appeared for the purpose of assisting these owners including Every Man His
Own Doctor or the Poor Planter's Physician
printed in Williamsburg in 1734. The Virginia
colonists were developing their own style of society in which the medical practitioner was both
a tradesman and a craftsman . This combination
prevented the establishment of the guild system
under which their English counterparts would be
either an apothecary , physician , or barber surgeon , but not all three . The physicians regarded
themselves as professionals , the apothecaries
were craftsmen , and the barber surgeons were
considered tradesmen . On the other hand , the
Virginia practitioner did what was needed , diagnosed his cases , dispensed his own medicines,
and engaged in what surgery he could . He was
a multi-specialist.
As the colonists started to prosper, less
time had to be spent on mere survival, and with
· increasing prosperity a plantation owner might
be able to afford to send his son abroad for five
to si x years of medical education . Whether
learning medicine by the apprentice system in
Virginia or studying at one of the major European universities, the student was still exposed
to botany which remained a significant part of
the curriculum . Even those who trained to be
physicians in the European sense often had
such titles as surgeon-apothecary or physicianapothecary when they returned to Virginia to
practice. Usually these new physicians retained
their keen interest in botany , not only out of a
need to find remedies to cure New World ills,
but also for the purpose of classifying the abundant flora . The improving conditions in America
gave these developing "aficionados " the opportunity to increase their knowledge of plants.
At that time there was growing world interest in
the classifica,tion of fauna and flora , and it was
frequently the physician , astute in botany , who
made significant contributions.
Dr John Clayton of Gloucester County, a
self-educated physician , wrote what is considered to be the best treatise on American plants,
namely Flora Virginica. It was first published in
1 739 in Leyden under the name of a Dutch botanist. Hence , Dr Smith-Barton is credited with
the first " notable " American treatise on the
subject - " Elements of Botany, " published in
1 803. He was a professor of medicine at the
University of Pennsylvania and was noted for his
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objections to the popular theory of ' 'similia similibus " or " like by like." This implied that every
country possessed the remedy for the diseases
which prevailed there . A fine example of this is
Polygala Senega or rattlesnake root . Not only
was this plant found in the terrain inhabited by
the rattlesnake, but the observer, with a little
imagination , might conclude that the root
looked like the tail of a snake .
Both Dr John Mitchell of Urbanna, Virginia, and Dr Alexander Garden of South Carolina contributed vastly to the describing of new
genera of plants. Dr Mitchell is credited with 25
genera of plants , eJ.nd he also described the life
cycle and reproductive mechanism of that curious American animal, the opossum . He was
well educated, having been trained in Edinburgh, and subsequently having made contributions in other areas of natural history. Dr Garden
also studied at the University of Edinburgh . He
is described as the "parable of the opportunities, temptations and limitations of American
life.'' He was perhaps the most accomplished
American botanist of his time, yet he never produced a significant systematic work . Most of his
correspondence was via letters to other notable
naturalists, and hence his name appears more
often than any other Ar:nerican in the famous
work by the Swedish botanist , Carl Linnaeus ,
entitled Systema Naturae (12th edition). Dr Garden is remembered by many for the sweet smell
of the gardenia, a flower which bears his name.
Plant identification and description were
also tempered by the accepted medical practice of the time . In 1 760 , Dr William Douglas
described the traditional approach as " bleeding , vomiting , blistering , purging, and anodynes , etc ., and if the illness continued there
was repetendi , and finally murderandi. " Another physician, John C. Lettsom , who lived in
England at this time , summed up the common
theories thus :
When any sick to me apply ,
I physicks , bleeds , and sweats 'em.
If after that they choose to die,
What's that to me? I Lettsom .
Bleeding was done by the ubiquitous
leech or by a special instrument known as a
fleam. The colonists , already concerned with
preventive medicine, would bleed themselves
often according to a schedule in hopes of pre-

venting an affliction . There seemed no limit to
the amount a person could be bled except exsanguination . It has been said that George
Washington, who had pneumonia, was probably bled to death as a "cure " for his infection .
Bleeding may have been popular, but
equally in demand were emetics. There were
many ''excellent'' agents available to induce
vomiting . The most widely used at that time,
and a drug still recognized today, was tartar
emetic (antimony potassium tartrate). In addition
to its properties as an emetic , it was used to
treat parasitic infections and today is of use intravenously as a treatment for schistosomiasis,
mainly of the japonicum type . Although inexpensive and effective, its application is limited
by highly toxic side effects including exfoliative
dermatitis, toxic liver necrosis, and toxic myocarditis .
lpecacuanha, another popular emetic , is
well known to today's pediatrician. Its original
use was not only as an emetic but also as a
treatment for diarrhea. The native Brazilians had
recognized its effectiveness in dealing with this
symptom prpbably in cases of amebiasis and
sold it in 1658 to the French as a secret remedy
for dysentery. The source of the "secret" remedy is the dried rhizomes of Cephaetis ipecacuanha or Acuminata ipecacuanhae.
These two methods, bleeding and vomiting , were used in hopes of ridding the body of
its poisonous affliction , and if they failed , the colonial physician could resort to blistering . For
this purpose , mustard seeds were ground and
mixed to form a paste which was applied to the
skin in the form of a poultice or plaster. If the
mustard seed failed to draw the poison to the
surface , a paste made from dried Spanish Fly
(Lytta cantharida vesicatoria) was applied to the
skin . This was considered a powerful vesicant
and surely would not fail, and if taken internally,
it had the additional properties of a diuretic and
aphrodisiac .
Diaphoresis was another means of expelling the unwanted humors from the body ,
and a tea made from the root bark o'f Sassafras
served the purpose well. The overtaxed colonist, as well as the physician , found use for this
for an interesting reason. When English goods
were boycotted in an attempt to repeal the
Townsend Acts , there was a shortage of fine
English tea , and Sassafras was substituted . The
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colonists soon realized that Sassafras was better
left off the shelf as a medicinal , but their desire
for English goods did not stop a revolution. Although diaphoresis was desirable, fevers were
not, and for these , the sought-after remedy was
cinchona or ' 'Peruvian bark. ' ' The colonial physician had the Jesuit missionaries to thank for
recognizing its properties in curing malaria or
relapsing fever . The active ingredient , not
known at the time, was quinine, and today a derivative of it, namely quinidine, is used as an
antiarrhythmic and as a means to relieve
muscle cramps .
Cathartics, also known as purgatives,
were a great mainstay of treatment, and the colonial physician frequently relied on botanical
remedies such as jalap , ipecacuanha, and rhubarb . In some instances , cathartic concoctions
were significantly popular to carry the name of
the originator . One example is P: Rudii, a rolled
pill named after Eustachius Rudius , and it contained colocynth (also known as bitter apple
and bitter cucumber) , Scammony (residue of
the plant Convo/vu/us Scammonia) , Turpeth
root , Socotrine aloes (from an aloin); cinnamon ,
cloves, spirits of wine , salt of tartar , and Black
Helebore root. It was claimed that it was even
effective in the treatment of some " social diseases."
Pain relievers and sedatives were just as
much in demand then as they are today, and
opium headed the list. The abundant ' 'Jamestowne weed ,' ' Datura stramonium was the local
source of a narcotic-like drug . It was a sedative
and anti-spasmodic in small doses, but in
higher doses it was hallucinogenic , though colonists praised this plant for its "cooling effects ."
For the more minor pains, the physician might
rely on a local anesthetic ; for example , the pain
of a common sore throat was relieved by a
gargle prepared from alum . In colonial days a
more drastic use of alum was to pack the uterus
in case of post-partum hemorrhage , but in modern times it is a spice used in canning.
No list of medicines would be complete
without mentioning three of the more all-purpose substances praised by the early colonists
and used by the colonial physician to maintain
his patients ' general well-being . Po/yga/a Virginina, better known as seneca rattlesnake root
was considered a reliable treatment. Its application was varied , and its reputation , according
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to William Byrd II , "increases every day." Byrd
noted that, ''The tincture of it has done wonders
in the gout------ . By its purging, its diuretick, and
diaphoretick qualities it is of great use in the
dropsy----- of great efficacy in Pleuretick Feaver
------ (and) a specifick against worms------ for the
pite of a mad dog------ it may be perhaps as
sure a remedy , as for the bite of a rattlesnake .''
Byrd also commented on the attributes of
the popular aromatic licorice-like woodland
herb , ginseng: "The earth has never produced
any vegetable so friendly to man as Ginseng. I
tiave found it very cordial and reviving after
great fatigue , it warms the blood, frisks the spirits, strengthens the stomach and comforts the
bowels exceedingly. All this it performs without
any of those naughty effects that might make
men too troublesome to their poor wives. ' '
Although the colonial physician may not
have recognized the lack of medicinal value of
rattlesnake root and ginseng , he probably never
doubted the increasing popularity of tobacco.
Tobacco was the New World plant that would
make men rich. Little did the early colonist
guess its future role in medicine . Tobacco was
not only profitable as a luxury commodity but
also as a remedy , for it "purgeth superfluous
fleame and·other gross humors, openeth all the
pores and passages of the body .. . . '' It was
also claimed that tobacco could heal gout and
ague , cure hangovers, and reduce fatigue and
hunger. Of the more than 2,000 agents identified in tobacco , the best known is nicotine,
which may decrease fatigue and curb the appetite . Despite the custom of not inhaling, the seventeenth-century smoker spent much more time
tending his long slender pipe which may have
kept him from falling asleep or eating too much .
Tobacco probably did little for the colonist's
swollen great toe or the fevers of malaria. Who
would have thought that such a profitable weed
could lead to some of the terminal diseases of
today?
The colonists were certainly imaginative in
their approach to medical treatment, drawing
both on the standard remedies , as well as na~
tive plants. What emerged was a multi-specialist
apothecary-physician , vital to the community as
were cultivation and identification of the local
plants to him . One has only to think of how frequently digitalis is prescribed to realize that
even as modern physicians without an herb gar-
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den in our backyard, we certainly have one in
our doctor's bag .

Boorstin , D.J. The Americans: The Colonial Experience.
New York, Vintage Books, 1958.
Ford , T.K. The Apothecary in Eighteenth-Century Williamsburg. Williamsburg , Colonial Williamsburg Foundation ,
1965

Transcribed from a talk given in a Senior Elective in the History of Medicine at the Medical College of Virginia , May
1980. Sources used in preparation were:

Gill " H.B., Jr. The Apothecary in Colonial Virginia. Charlottesville, University Press of Virginia, 1972.
Every Man His Own Doctor, 2 ed. Williamsburg, Printing Of-

fice, 1971 (reprint of 1 734 edition)
Blanton, W.B . Medicine in Virginia in the Seventeenth Century. Richmond, William Byrd Press, 1930.

Bill Cabbell, Curator, Colonial Williamsburg Apothecary
Shop (personal communication)
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